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 Chk2 is a cell cycle checkpoint kinase that is essential for initiating the DNA 
damage response in the presence of genetic damage.  Its role is highly conserved from 
budding yeast (where it is named Rad53) to humans. Very few cell cycle checkpoint 
proteins have ever been studied in fish and the role of Chk2 has never been characterized. 
Oncorhynchus mykiss (Rainbow trout) was chosen for this project due to its importance 
in the commercial aquaculture industry and the availability of rainbow trout cell cultures 
at the University of Waterloo.  This study was the first to clone the CHK2 gene in a 
teleost species, verified through both genomic and cDNA cloning. A section of the CHK2 
gene, specifically the forkhead associated domain (FHA), was used to express 
recombinant Chk2 protein and generate polyclonal anti-Chk2 antibodies. A southern blot 
was performed and CHK2 was found to exist as a single copy number in the rainbow 
trout genome.  The tissue specificity of Chk2 was also examined both at the mRNA 
transcript and protein level.  Interesting tissue specific differences were discovered with 
transcript levels moderately low in gill and higher in brain, while protein levels were 
extremely high in gill and lower in brain tissues.  Protein levels were verified in both 
whole fish tissue samples and in cell culture suggesting that cell cultures accurately 
reflect the state of checkpoint proteins in vivo.  These tissue specific differences suggest 
that in gill, Chk2 is maintained at a high protein level to combat any toxins in the water 
attempting to transverse this barrier tissue and gain access to the fishs circulatory 
system.  Meanwhile, the blood brain barrier offers protection to the highly sensitive brain 
tissue, suggesting that high levels of Chk2 protein are not constitutively required, but 
instead remain in a transcript reservoir able to be quickly translated in the event of DNA 
 iv
damage.  To determine whether Chk2s checkpoint role is conserved in O. mykiss, both 
gill and brain cell cultures were treated with low and high doses of bleocin (a 
commercially available form of bleomycin) known to cause high levels of double-strand 
breaks, the most deleterious type of DNA damage and a specific activator of the Chk2 
DNA damage response (DSB).  Results showed that bleocin had no effect on levels of 
Chk2 in gill cells, confirming that the protein is constitutively active in this tissue always 
on alert against potential genetic insult.  In contrast, brain cells were able to upregulate 
Chk2 in a dose-dependent manner to bleocin induced DNA damage demonstrating that 
Chk2 can act as a biomarker for genetic damage in brain cells.  In conclusion, the tissue 
specific expression of Chk2 and its ability to respond to DNA damage suggests that 
checkpoint proteins may serve as suitable biomarkers for DNA damage in O. mykiss and 
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1.1 The Cell Cycle 
The eukaryotic cell cycle is a series of tightly controlled events that results in the 
faithful transmission of genetic information through generations of cells.  It is comprised 
of four phases: G1, G2, S (synthesis) and M (mitosis) as illustrated in Figure 1.1.  The G1 
and G2 gap phases can be extremely short in unicellular organisms but are much longer 
and easier to observe in mammalian cells versus other cell cycle stages. There are two 
major events that occur within the cell cycle, the S phase encompasses the replication of 
cellular DNA and the M phase is when the chromosomes become equally divided 
between two identical daughter cells (2).  Before entering S phase, a multi-protein 
complex called the pre-replicative complex (Pre-RC) is assembled on DNA at replication 
origins scattered throughout the nuclear chromosomes (3).  During S phase, pre-RCs 
initiate replication by promoting origin unwinding and facilitating the recruitment of 
DNA polymerases.  DNA strands are then synthesized at the astonishing rate of 500 
nucleotides per minute with an error rate of only one nucleotide in a billion (3).  In M 
phase (mitosis), cells partition their newly replicated nuclear DNA into two identical 
daughter cells, ending with an event called cytokinesis where the cytoplasm and cell 
membrane are also divided (4).  In the G1 phase of the cell cycle, the cell increases in 
size and starts synthesizing RNA and proteins in preparation for S phase, such as DNA 
polymerases and topoisomerases.  In the G2 phase, the cell continues to grow and 
produce mitotic proteins to ensure proper chromosomal segregation and the viability of 
the newly formed daughter cells (5).  In order to correctly duplicate the genome during 








Figure 1.1:  The Eukaryotic Cell Cycle. During the G1 gap phase, the cell grows in size 
and synthesizes the proteins it will need to replicate its genome. In S (synthesis) phase, 
the chromosomes duplicate as a result of DNA replication.  In the G2 gap phase, the cell 
continues to grow in size and synthesize the proteins it will need for proper cell division. 
During the M (mitosis) phase the chromosomes separate in the nucleus and the division 
of the cytoplasm (cytokinesis) occurs. There are checkpoints in the cycle at the end of G1 
and G2 that can prevent the cell form entering the S or M phases of the cycle. Cells that 
are not in the process of dividing are in the G0 stage. Adapted from Houtgraaf et al. (5).  
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Maintenance of genomic integrity is vital for the survival of eukaryotic cells, 
while failure to do so may result in the accumulation of mutations, oncogenesis, and/or 
cell death(6).  
1.2 Cell Cycle Checkpoints 
Within the nucleus DNA is constantly under threat from exogenous damaging 
agents and harmful cellular metabolites, such as reactive oxygen species (2;7).  DNA 
damaging agents such as ionizing radiation, UV light and chemotherapeutic agents are 
being used more and more to treat serious diseases such as cancer and arterial stenosis in 
an effort to kill cells that are undergoing aberrant cell division (5) .  In order for 
proliferating cells to move successfully through all stages of the cell cycle, they have 
developed cell cycle checkpoints which serve to control the rate of progression, to 
monitor the integrity of the DNA being copied, and to initiate DNA repair when 
necessary (8). Checkpoints act by arresting cell cycle progression until the DNA damage 
can be repaired or alternatively can activate an apoptotic pathway if the damage is too 
severe to be repaired successfully.  Many proto-oncogenes have been implicated in 
regulation of the cell cycle and in the DNA damage response (9). 
The first checkpoint genes were discovered in 1976 by Hannan and Nasim. They 
identified fission yeast strains with mutations in RAD1, RAD3 or RAD9 that were unable 
to delay cell cycle progression after treatment with UV radiation (10).  From this study 
they concluded that cell cycle delay is an active part of the DNA repair process and not 
simply due to damage induced by UV exposure. In the early 1980s, it was discovered that 
cells from patients with ataxia telengiectasia (A-T) failed to elicit proper cell cycle delay 
after irradiation exposure.  A-T is an inherited disease associated with an increased risk  
 of sporadic tumor development.  This research provided the first link between failed cell 
cycle delay and cancer (11).  
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The events that occur within the DNA damage response form a signal 
transduction cascade, with sensor proteins detecting the damage and relaying the signal to 
mediator or transducer proteins that ultimately act on effector proteins, determining the 
specific outcome of each checkpoint event (12;13).  Within the cell nucleus the amount 
of undamaged DNA vastly exceeds that of damaged DNA, yet sensor proteins are still 
able to carry out damage recognition although discrimination is not always absolute.  
Sensor proteins are in constant contact with DNA always searching for areas that might 
require repair, therefore checkpoints are not really an on or off type of event, but are 
more accurately viewed as a steady presence always surveying for damaged genetic 
material (12;14). Stalled replication forks, DNA strand nicks, base-pair mismatches, 
RPA-coated single stranded DNA, double strand breaks, and DNA cross-links are all 
indications that DNA damage has occurred (15).  Once the DNA strand has been exposed 
to a DNA damaging agent DNA lesions, adducts or abasic sites typically form providing 
higher-affinity binding for sensor proteins (14). The proteins involved in the DNA 
damage response are also involved in regulating the transition points between G1/S, 
G2/M and intra-S phase providing further evidence to the theory that checkpoint 
pathways are operative under normal growth conditions and simply become amplified 
once an increase in DNA damage is detected (14).   
1.2.1 Sensor Proteins 
There are two main groups of checkpoint damage sensors, the phosphoinositide 3-
kinase-like kinase (PIKK) family members, ataxia-telangiectasia-mutated (ATM) and 
ATM and Rad-3 related (ATR) and the RFC/PCNA (clamp loader, polymerase clamp)-
related Rad17-RFC/9-1-1 complex (12;16).  The first step in the DNA damage response 
is the recognition within the cell that DNA damage has occurred.  In both mammals and 
yeast, Rad9, Rad1, Hus1 and Rad17 are all essential for sensing damage and activating 
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checkpoint responses (17).  The Rad17-Replication Factor C (RFC) complex is globular 
shaped with a deep grove running down its length which allows it to bind along the DNA 
strand (18),  while the 9-1-1 (Rad9-Rad1-Hus1) complex has a similar homotrimer ring-
like structure to that of the PCNA replication complex, a clamp-like structure that 
encircles DNA (19).   
The Rad17-RFC complex is activated only during a checkpoint response, but is a 
structural homolog of the RFC replication factor, which is active throughout S phase.  
RFC is a heteropentamer composed of p140, p40, p39, p37 and p36 involved specifically 
in DNA replication.  ATP-dependent structural changes in RFC promote the loading of 
the PCNA clamp onto DNA, as shown in Figure 1.2 A), which is required for efficient 
strand synthesis by DNA polymerase δ, a eukaryotic replicative polymerase.  Both PCNA 
and RFC are essential for the functional assembly of the replication fork complex (20). 
 The Rad17-RFC complex is very similar to RFC, only the Rad17 protein replaces 
the p140 subunit (21). During a checkpoint response Rad17-RFC binds to the site of 
damaged DNA and recruits the 9-1-1 complex, as shown in Figure 1.2 B). Rad17-RFC 
then acts as a DNA-stimulated ATPase binding to both DNA and the 9-1-1 complex 
simultaneously (22). It then loads the 9-1-1 complex onto DNA in a clamp-like manner 
which has been effectively demonstrated in both budding yeast and humans (23;24). The 
chromatin-bound 9-1-1 complex then facilitates phosphorylation mediated by ATM and 
ATR (23;25). ATM and ATR share partially redundant functions within a cell cycle 














Figure 1.2: Schematic of RFC and PCNA in DNA 
Replication.  
A) RFC loads PCNA clamp onto DNA, hydrolysis 
of ATP dissociates the complex.   
B)  Proteins involved in the initiation of DNA 
replication under stressed conditions in Xenopus 
including the RFC-Rad17 and 9-1-1 complex. 




in Figure 1.3 (26). ATM is an oligomeric protein approximately 350 kDa in size and 
exhibits protein kinase activity in response to double-strand breaks (DSB) in vivo (27)  
and to linear DNA in vitro (28).  Mutations in ATM (ataxia telangiectasia mutated) cause 
A-T in humans as described above.  Cells lacking ATM are viable, suggesting that ATM 
is not essential for normal cell cycle progression (23;29).  Once activated in response to 
DNA damage, ATM monomerizes and becomes capable of phosphorylating many 
downstream targets including Chk2, p53, NBS1, BRCA1 and itself (30).  ATM 
autophosphorylation is regulated by PP2A which it binds constitutively in the absence of 
DNA damage, but rapidly dissociates from once DNA damage has been detected (31).  
ATMs kinase activity is monitored in part by MRE11, which enhances its ability to 
phosphorylate downstream targets, and within the MRN complex helps to localize ATM 
to sites of DNA damage (32). The MRE11RAD50NBS1 (MRN) protein complex has 
been linked to many DNA metabolic events that involve DNA double-stranded 
breaks. MRN is one of the first factors to be localized to the DNA lesion, where it 
might initially have a structural role by tethering together, and therefore stabilizing, 
broken chromosomes (33). ATM is also regulated through a single major damaged 
induced phosphorylation site at Ser198 (humans), which permits a rapid and sensitive 
switch for checkpoint activation (30).  The monomerization and autophosphorylation of 
ATM does not require the protein to bind to damaged DNA, but seems to be orchestrated 
instead by changes in higher-order chromatin structure which ATM can sense from a 
distance (30) .   
ATR was discovered by Cimprich et al. through the human genome database with 
sequence homology to ATM and S. pombe Rad3, giving it the name ATR (ATM and 








Figure 1.3: Schematic of DNA Damage Proteins. ATR and ATM are the central 
proteins regulating checkpoint responses to various forms of DNA damage. Activation of 
ATR and its downstream effects are indicated in red, whereas activation and downstream 
effects of ATM are indicated in blue (not absolute; some exceptions of overlapping 
function do occur). Signals and downstream effects common to both kinases are 







mammals (36).  Partial loss of ATR activity in humans is associated with the inherited 
disorder Seckel disease, which has many shared characteristics with A-T (37).  ATR does 
not recognize DSB, but is activated preferentially by UV-induced DNA damage and by 
DNA damaging agents that result in inhibition of DNA replication (ex. hydroxyurea   a 
ribonucleotide reductase inhibitor that depletes dNTP pools) (38).  ATR is recruited to 
DNA through an intermediate DNA-binding partner known as ATRIP (ATR interacting 
protein), which allows the complex to bind to RPA coated single-stranded DNA rather 
than naked DNA (39).  When damage does occur, single-stranded DNA (ssDNA) 
becomes coated with replication protein A (RPA), which stimulates the binding of 
ATRIP to RPA.  ATR is also critical for cellular responses to stalled replication fork 
progression caused by DNA damage directly or indirectly through other stresses (29;38). 
It shows no measurable change in kinase activity in the event of DNA damage, 
suggesting it may be constitutively ready to phosphorylate its downstream targets (38).  
Instead, its cellular functions seem to be largely controlled by its subcellular localization.  
Since ATRIP is complexed with ATR, this binding demonstrates a way that the 
subcellular localization of ATR can be changed in response to DNA damage (39).  In 
response to many genomic stresses both ATM and ATR are eventually activated working 
in unison to elicit an appropriate checkpoint response.   
In human cells, an alternative mechanism for DNA damage recognition has also 
been elucidated.  It has been shown that the interaction of checkpoint sensors with DNA 
repair molecules may help to recruit them to sites of DNA damage.  In a study by Wang 
and Qin in 2003, it was shown that ATR can associate with Msh2, a protein involved in 
mismatch repair (40).  In a subsequent study by Giannattasio et al., it was also shown that 
Rad9, a subunit of the 9-1-1 clamp, can interact with nuclear excision repair protein, 
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Rad14 in response to UV-induced DNA damage (41).  Further research is required to 
confirm whether the interaction between checkpoint sensor proteins and DNA repair 
proteins is an essential component of the DNA damage response.   
1.2.2 Mediator Proteins 
Once DNA damage has been sensed the signal must be relayed to appropriate 
downstream targets.  Mediator proteins associate with damage sensing proteins and  
signal transducer proteins to help provide specificity within the signal transduction 
cascade (14). A classic example of a mediator protein from S. cerevisiae is Rad9, which 
is specifically required to mediate the signal between Mec1 (ATR) and Rad53 (Chk2) 
(42).  In humans four specific ATM mediator proteins have been characterized: the p53 
binding protein, 53BP1; the topoisomerase binding protein, topBP1; the mediator of 
DNA damage checkpoint 1, MDC1, and the breast cancer susceptibility gene 1, BRCA1.  
All four proteins contain BRCT protein-protein interaction domains (43).  MDC1 has 
been shown to function as a bridge between histone H2A isoform γ (γ H2AX) and 
Nijmegen breakage syndrome 1 (NBS1) in the MRE11-Rad50-NBS1 (MRN) complex 
(44).  Mediator proteins are recruited to sites of DNA damage following the 
phosphorylation of γH2AX by ATM and become microscopically visible as foci on the 
DNA strand (45).  These mediators can then promote sustained multi-protein interactions 
and facilitate ATMs downstream signaling (45). ATR checkpoint signaling is mediated 
primarily through Claspin, which is an adaptor protein that is structurally unrelated to the 
other mediator proteins. Claspin interacts with chromatin in active replication forks and is 
required for ATR-mediated phosphorylation of Chk1 (46).  The importance of mediator 
proteins is highlighted by the fact that mammalian cells that lack any of the above-
mentioned mediators show enhanced sensitivity to DNA damaging agents and impaired 
intra-S phase and G2/M checkpoints (47).  
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1.2.3 Transducer Proteins 
In order to relay the checkpoint signal, two signal transducer kinases, Chk1 and 
Chk2, become activated.  These serine/threonine kinases were first identified in mammals 
based on sequence similarity with yeast Chk1 and Rad53/Cds1, respectively (12). In 
general, Chk2 is activated by ATM in response to double strand breaks and Chk1 is 
activated by ATR after UV-induced damage (38), although some overlap in their actions 
does exist and will be discussed in more detail below.  Chk1 is not essential for viability 
in fission yeast, but is required for viability in mammals suggesting that it may have 
acquired other functional roles.  A Chk1 deletion in mice results in early embryonic death 
due to loss of microtubule integrity and gross chromosomal abnormalities within the cell 
nucleus (48). Chk1 is phosphorylated in an ATR-dependent manner at two serine 
residues, Ser317 and Ser345 (mammalian numbering), in response to DNA damage in 
both yeast and mammals (49).  Chk1 activity is also greatly reduced in cells with 
decreased levels of  Rad17 or lacking Hus1 (50).  Chk1 has been shown to phosphorylate 
Cdc25A, Cdc25B and Cdc25C, which downregulates their phosphatase activity causing 
cell cycle arrests within the DNA damage response.   
Chk2 is not required for prenatal development in mice, but is an integral 
component of the DNA damage signaling pathway(51).  Chk2 is activated through either 
upregulation or phosphorylation of the threonine residue T68 in mammals in an ATM-
dependent manner in response to ionizing radiation (IR) treatment (52).  Mutations in 
human Chk2 are responsible for Li-Fraumeni syndrome which causes an increase in 
sporadic tumor incidence (53).  Chk2 phosphorylates many downstream targets including 
Cdc25A, Cdc25C, BRCA1, and p53, as shown in Figure 1.4 (13).  Chk2 seems to be 










Figure 1.4: Targets of Chk1 and Chk2 in Human Cells. Following their activation, 
Chk1 and Chk2 phosphorylate unique (green and red, respectively) and overlapping 
(blue) downstream effectors that further propagate the checkpoint signaling. The known 
target sites of Chk1 (green), Chk2 (red), and both Chk1 and Chk2 (blue) on the individual 
substrates are shown. Some of the Chk1/Chk2 downstream effectors are classified as 





1.2.4 Effector Proteins 
Cell cycle effector proteins are ultimately responsible for instigating cell cycle 
arrest, DNA repair or apoptosis.  In humans, the Cdc25 proteins (A,B,C), are 
phosphatases that de-phosphorylate cyclins to promote down cell cycle transitions (56).  
When the Cdc25 proteins are phosphorylated in response to DNA damage they become 
inactivated either by nuclear exclusion or proteolytic degradation (56).  Studies in 
mammals and in Xenopus have shown that phosphorylation of the Cdc25 family results in 
the creation of binding sites for 14-3-3 proteins (highly conserved cellular proteins that 
are known to regulate various oncogenes and tumor suppressors), which ultimately 
causes their phophatase activity to be downregulated (57).  For example, within the intra-
S phase response activated Chk1 phosphorylates Cdc25A causing it to be degraded.  
Without Cdc25A, cyclin Cdk2 does not become activated which blocks the loading of 
Cdc45 onto chromatin.  Cdc45 is required for the initiation of DNA replication through 
recruitment of DNA polymerases to the pre-replicative complex (58).  The p53 tumor 
suppressor protein is another major effector protein and can direct the cell to undergo cell 
cycle arrest or apoptosis in response to DNA stressors (59).  p53 activity can be modified 
through phosphorylation, sumorylation, neddylation and acetylation (60).  p53 is 
negatively regulated by Mdm2 which causes any excess p53 within the cell to be targeted 
for degradation or to be exported from the nucleus (61).  Upon DNA damage, p53 can be 
phosphorylated by ATM, ATR or Chk2 which inhibits the interaction between p53 and 
Mdm2 resulting in the accumulation of stable p53 (62).  To help reinforce this 
stabilization, ATM also phosphorylates Mdm2 reducing its ability to successfully bind 




1.3 Checkpoint Events 
1.3.1 The G1/S Checkpoint 
 The G1/S checkpoint inhibits the initiation of DNA replication at the G1/S 
transition in the presence of DNA damage as shown in Figure 1.5.  Under normal 
conditions, cells commit to enter S phase at a stage called start in S. cerevisiae or the 
restriction point in mammalian cells (64).  In the presence of DNA damage, entry into 
S phase is prevented regardless of whether or not this restriction stage has been reached.  
In the event of double strand breaks caused by IR or radiomimetic agents, ATM becomes 
phosphorylated and activates both p53 and Chk2.  ATMs actions initiate two distinct 
signal transduction cascades, one to initiate and one to maintain the G1/S arrest (56).  To 
initiate the arrest, Chk2 phosphorylates Cdc25A causing it to be exported from the 
nucleus and degraded (65).  As described above, lack of Cdc25A results in the 
accumulation of phosphorylated (inactive) Cdk2 which can no longer phosphorylate 
Cdc45 to initiate DNA replication (58).  If the damage is caused by UV radiation the 
signal is sensed by ATR, Rad17-RFC and the 9-1-1 complex leading to ATR dependent 
Chk1 phosphorylation.  Chk1 can then phosphorylate Cdc25A resulting in G1 arrest as 
described above (14).  Irrespective of the initial response pathway, the maintenance of the 
G1/S arrest is p53 dependent and only becomes fully sustained well after the damage is 
initially detected (56). In the maintenance stage, p53 is directly phosphorylated by either 
ATM (or ATR) which inhibits its nuclear export and degradation, resulting in the 
accumulation of p53 within the nucleus (66). Additionally, the ubiquitin ligase Mdm2 
that normally binds p53 and targets it for degradation is inhibited by both ATM and ATR 







Figure 1.5: The G1/S Checkpoint in Mammals. The proteins involved in the G1/S 
checkpoint work together to block Cdk2-cyclin E activity. This is achieved by stabilizing 
p53 and degrading Cdc25A to maintain Cdk2 inhibitory phosphorylation. Gray arrows 
denote functions that are lost upon activation of the checkpoint cascade, and labeled 




cyclinE S-phase promoting complex, effectively maintaining the G1/S arrest.  p21WAF-
1/Cip1 also binds to the Cdk4-cyclinD complex, preventing it from phosphorylating Rb. 
In order for the transcription of S phase genes to proceed the transcription factor E2F 
needs to be released from Rb, which can only occur once Rb has been phosphorylated 
(67) thereby providing a sustained G1 block.  The p53 pathway and the Rb pathway are 
arguably the most commonly deregulated pathways in human cancers (47).  
1.3.2 The Intra-S-Phase Checkpoint 
 The intra-s-phase checkpoint can be activated either by damage encountered 
during replication or by earlier damage that was not initially detected at the G1/S 
transition.  It is typically characterized by largely transient, reversible inhibition of 
origins of DNA replication that have not yet fired.  The replication fork itself can be 
slowed down actively through the binding and sequestration of PCNA by p21WAF-1/Cip1 or 
by the degradation of PCNA by Rad6 in budding yeast (67).  There are many checkpoint 
and repair proteins involved in the intra-s phase checkpoint as shown in Figure 1.6.  In 
the event of a double strand break ATM, the MRN complex and BRCA1 are all required 
for checkpoint activation (68) and the initiation of the signal transduction cascade.  The 
ATM-Chk2-Cdc25A-Cdk2 pathway acts as described above, with the inhibition of Cdk2, 
preventing the loading of Cdc45 onto chromatin, which in turn prevents the recruitment 
of DNA polymerases and late origin firing (69).  There is also a second pathway that is 
activated in the intra-S phase response.  SMC1 is phosphorylated by ATM in conjunction 
with BRCA1, FANCD2 (Fanconi anaemia complementation group D2), and NBS1, and 




Figure 1.6: The Intra-S Phase Checkpoint in Mammals in response to DSB. In 
response to double-strand breaks induced by ionizing radiation, ATM triggers two 
cooperating parallel cascades to inhibit replicative DNA synthesis. ATM, through the 
intermediacy of MDC1, H2AX, and 53BP1, phosphorylates Chk2 on Thr68 to induce 
ubiquitin-mediated degradation of Cdc25A phosphatase. The degradation locks the S 
phasepromoting Cyclin E/Cdk2 in its inactive, phosphorylated form and prevents the 
loading of Cdc45 on the replication origin. ATM also initiates a second pathway by 
phosphorylating NBS1 of the MRN complex, as well as SMC1, BRCA1, and FANCD2. 




activate the S-phase recovery process (70).  Cell cycle checkpoint mediators, γH2AX, 
53BP1, BRCA1, Mre11, and SMC1 colocalize through MDC1 at sites of DSB to form 
ionizing radiation induced foci (IRIF) initiating DNA repair mechanisms as required (44).   
 When DNA is damaged by UV-radiation or by chemicals that cause bulky DNA 
adducts, ATR acts as the main damage sensor.  In conjunction with its chaperone protein, 
ATRIP, ATR binds either directly to chromatin or to RPA-coated single stranded DNA 
where it becomes activated (39).  Similar to the G1/S checkpoint, the ATR-Chk1-
Cdc25A-Cdk2 pathway becomes activated and origins are prevented from firing (71).  
There is also evidence from Xenopus studies that ATR-dependent checkpoints may also 
downregulate Cdc7-Dbf4 kinase activity, which is required for Cdc45 to bind chromatin 
(72).  ATR also promotes recruitment of checkpoint mediator proteins such as MDC1, 
BRCA1, and SMC1, which are essential for orchestrating DNA repair and reinitiating 
DNA replication (73).   
1.3.3 The G2/M Checkpoint 
 In the presence of DNA damage the G2/M checkpoint prevents cells from 
undergoing mitosis as shown in Figure 1.7.  Again, the initial response pathway is 
dependent on the type of DNA damage.  The ATR-Chk1-Cdc25 pathway is activated in 
response to UV-damage and the ATM-Chk2-Cdc25 pathway is activated in response to 
IR. Upon phosphorylation, the Cdc25 phosphatase binds to the 14-3-3 proteins, becomes 
sequestered in the cytoplasm and is degraded by the ubiquitin-proteasome pathway (74).  
Next, Wee1 becomes upregulated, which in combination with the degradation of Cdc25 
inhibits Cdc2/Cyclin B activity and prevents the cell from entering mitosis (75). Initially, 
it was believed that Cdc25C was the primary effector of the G2/M checkpoint. However, 
a study using Cdc25C (-/-) murine cell lines was found to have a normal G2/M response, 
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while disruption of the Chk1-Cdc25A pathway completely abrogated the checkpoint, 
pointing to Cdc25A as the major G2/M effector (76;77).   
1.4 Checkpoints and Cancer 
 DNA damage from both endogenous and exogenous sources is a major 
contributor to the development of human cancers, thus malfunctioning cell cycle 
checkpoints may be linked to cancer incidence and progression.  When cells have an 
intact DNA damage response they are able to arrest progression through the cell cycle, 
initiate repair, or promote apoptosis in response to genetic insult.  Mutations in these 
checkpoint proteins permits cells to divide uncontrollably and allow the accumulation of 
cells with genetic mutations (47).  Many of the above-mentioned proteins have been 
classified as either tumor-suppressors or proto-oncogenes, but determining exactly which 
proteins would be useful targets in chemotherapeutics remains an ongoing challenge. 
Mutations in ATM lead to an increased rate of lymphomas in both humans and mice (29).  
Studies in ATM-deficient mice have found that excessive recombination, normally 
mediated by ATM, may be an important contributor to tumorigenesis in ataxia-
telangiectasia patients (A-T) (78).  Low levels of ATR expression have been linked to 
Seckel syndrome which causes growth retardation, dwarfism, microcephaly, mental 
retardation and chromosomal instability (79). 
In mice that are defective in DNA mismatch repair, low levels of ATR expression 
have also been associated with increased tumorigenesis (80).  Mice lacking either γH2AX 
or 52BP1 show defective cell cycle checkpoints and cancer predisposition, although no 
link has been clearly established in humans (81;82).  Chk1 (+/-) mice also show a modest 







Figure 1.7: The G2/M Checkpoint in Mammals. The G2 checkpoint in mammalian 
cells primarily functions to block Cdc2-cyclin B activity. The common means of 
maintaining Cdc2 inhibitory phosphorylation is by blocking Cdc25A phosphatase 
activity, namely by promoting its association with 14-3-3-proteins. Gray arrows denote 
functions that are lost upon activation of the checkpoint cascade, and labeled amino acids 





accumulation of DNA damage, and inappropriate mitotic entry (83).  Chk2s relationship 
to cancer will be discussed below in section 1.5.5. 
1.5 Characterization of Checkpoint Kinase 2 
 Chk2 is a protein kinase  an enzyme that transfers the phosphate group from 
ATP to a given substrate target, causing a covalent modification.  Phosphorylation is a 
way for cellular proteins to become activated or inactivated, for them to interact with 
different protein partners, and a way for their subcellular localization to be changed.  This 
modification is used to initiate or spread a wide range of cellular signals in many 
different fundamental cellular processes (84). Double strand breaks (DSB) are among the 
most severe type of DNA damage and can be caused experimentally through ionizing 
radiation, through radiomimetic drugs that bind to DNA (such as bleomycin and 
neocarcinostatin), or through topoisomerase II inhibitors (such as etoposide and 
doxorubicin) (85).  The importance of Chk2 in the DNA damage response is indicated by 
its conservation across all eukaryotes studied to date, such as yeast, mice and humans.  It 
is not required for viability in vertebrate cells, but lack of Chk2 results in defective cell 
cycle checkpoints and apoptosis after induction of DSB (84).  Chk2 is preferentially 
activated in response to DSB by ATM, but in some cases can be activated by ATR 
depending on the exact type of DNA lesion.  In such cases where both ATR and ATM are 
activated, the ATM-Chk2 response is initiated first and appears to be more transient, 
where as the ATR response occurs after and is often more sustained (86).  Chk2 is 
expressed throughout the cell cycle due to its broad role in responding to DSB 





1.5.1 Domains of Chk2 
 The Chk2 protein is composed of three distinct domains, an SQ/TQ cluster 
domain (SCD), a forkhead-associated domain (FHA), and a Ser/Thr kinase domain as 
shown in Figure 1.8.  The SCD domain is the primary substrate target of ATM/ATR, and 
in humans the T68 residue has been shown to be a key phosphorylation site (88). In 
fission yeast, the phosphorylation of T11 in the SCD domain by Rad3 is required for 
Cds1 (Chk2) activation (89). The FHA domain is an 80-100 amino acid phosphopeptide-
binding region and is highly conserved from yeast to humans (90).  Structural analysis of 
the FHA domain in combination with x-ray crystallography has shown that it consists of 
eleven beta-pleated sheets forming a structural core with the connecting loops exposed 
for phosphopeptide recognition (91).  The kinase domain occupies almost the entire 
carboxy-terminal half of Chk2, and is similar to other Ser/Thr kinases with a glycine rich 
region near a section of lysine residues towards the N-terminal region and an aspartic 
acid acting as a catalytic residue at the active site (92).  Mutating one of the key residues 
in the human Chk2 kinase domain, Asp345, results in a kinase-defective mutant which 
has proven to be a valuable research tool (57).  The budding yeast orthologue of Chk2 
(named Rad53) is the only member of the Chk2 family to have a large carboxy-terminal 
extension that includes a second forkhead associated (FHA) domain (84).  A feature 
unique to mammalian Chk2 is a c-Abl SRC homology-3 (SH3) domain-consensus 
binding domain, which is located just upstream of the FHA domain.  The functional 
significance of this domain is unknown, but Chk2 and c-Abl are both phosphorylated and 






Figure 1.8: Domains of Chk2. Schematic of the Chk2 domains in humans, including the 
SQ/TQ, FHA and Kinase regions.  This figure also shows the mutations that have been 
identified so far in human cancers. Adapted from Takai et al.  (55). 
 
 
Figure 1.9: Activation of Chk2. A) In mammals Chk2 is phosphorylated by ATM/ATR 
on T68 in the SCD domain inducing a conformational change (dashed arrows) which 
allows Chk2 to autophosphorylate. B) Model of Rad53 activation in S. cerevisiae, in 
which Mec1-dependent, Rad9-mediated in trans autophosphorylation of two Rad53 
molecules leads to release of activated Rad53. Pinheads indicate phosphorylation. 




1.5.2 Details of Chk2 Activation and Regulation 
 Chk2 kinase activity is increased following DNA damage caused by IR and 
chemotherapeutic agents as described above.  More recently, telomere erosion leading to 
senescence has also been implicated as an activating signal for Chk2 (94).  In A-T cells 
that lacked a functional ATM protein, Chk2 failed to be activated and only after ectopic 
ATM expression could a Chk2-dependent intra-S phase checkpoint be restored (95).  
ATM has been shown to phosphorylate Chk2 specifically at T68 in human cell lines, and 
an alanine mutation of this residue prevented Chk2 activation after IR in vivo (96).  ATR 
has also been shown to activate Chk2 after high levels of UV exposure or after treatment 
with the ribonucleotide reductase inhibitor, hydroxyurea (HU) (97).  Chk2 normally 
resides in the cell as a monomer, but after DNA damage undergoes dimerization, with the 
SCD domain (containing the phosphorylated T68 residue) binding to the FHA domain in  
a neighbouring Chk2 protein (98).  Chk2 then undergoes multiple autophosphorylation 
steps ultimately resulting in kinase activation as shown in Figure 1.9 A) (99).  The T68 
phosphorylation event is only required for the initial dimerization and 
autophosphorylation of Chk2, and is not required for sustained Chk2 kinase activity 
(100).  Phosphorylation of various residues within the Chk2 protein may allow for stress 
specific differences in Chk2 kinase activity (57).   
In budding yeast, DNA damage leads to the rapid binding of Rad53 to a dimer of 
Rad9 (part of the 9-1-1 damage sensing complex).  This interaction between Rad53 and 
Rad9 is dependent on Rad9 first being phosphorylated by Mec1 (the budding yeast 
homologue of ATR) (101).  This event allows two Rad53 molecules to be brought into 
close proximity, and promotes their in trans autophosphorylation, as shown in Figure 1.9 
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B). This event in turn releases Rad53 from Rad9, allowing it to act on subsequent 
downstream targets (101).   
 Analyses of Chk2 in cultured mammalian cells have shown that it is primarily a 
nuclear protein, which would be expected for a protein involved in the DNA damage 
response (102).  However, in human neuronal cells Chk2 has a predominately 
cytoplasmic localization, which is also true of ATM in neuronal cells (87). This indicates 
that ATM and Chk2 may have an additional cytoplasmic role in the protection of 
sensitive neuronal cells perhaps in guarding against oxidative stress (38).  This 
hypothesis is supported by the fact that when neurons are exposed to reactive oxygen 
species they undergo apoptosis and patients who suffer from A-T suffer from severe 
neurodegeneration (103).  In humans, Chk2 is expressed to varying degrees in cells of 
proliferating and terminally differentiated, non-proliferating tissues and since Chk1 is 
restricted to primarily proliferating cells, the DNA damage response may rely more 
heavily on Chk2 in quiescent cells (87).   
1.5.3 Targets of Chk2 
 Chk2 can act on a variety of downstream effector targets, which in turn mediate 
the cell cycle arrest or apoptosis that characterize the DNA damage response as shown in 
Figure 1.10.  In vitro studies were able to show that Chk2 seems to preferentially 
phosphorylate the L-X-R-X-X-S/T consensus motif (104).  One of the most important of 
Chk2s downstream targets is the Cdc25 family of phosphatases, which in unperturbed 
cells promote cell cycle progression by activating the cyclin-dependent kinases Cdk2 and 
Cdk1 (65).   By phosphorylating Cdc25, Chk2 causes it to either be degraded or exported 
from the nucleus efficiently causing a cell cycle arrest (92).  The identification of the 







Figure 1.10:  Downstream Targets of Chk2.  Activated Chk2 induces rapid G1/S and 
G2/M cell cycle arrest and/or S-phase delay by phosphorylating Cdc25A. Chk2 also 
phosphorylates the p53 tumour suppressor, which results in stabilization of p53 and 
transactivation of p53's target genes. The p53-specific ubiquitin ligase Mdm2 might also 
be a substrate for the Chk2 kinase. Finally, Chk2 and ATM jointly phosphorylate the 
BRCA1 tumour suppressor. Chk2-dependent phosphorylation leads to dissociation of 
Chk2 from BRCA1, an event that is required for efficient repair of DSBs and survival of 





the clinically important radioresistant DNA synthesis (RDS) phenotype which allows the 
replication of DNA even in the presence of significant DNA damage.  When any of the 
components of this axis are disrupted RDS is the result, showing that this checkpoint is 
extremely important for maintaining genomic integrity (65).   
Chk2 can also phosphorylate E2F-1 in response to the DNA damaging agent 
etoposide, regulating both its stability and its transcriptional activity (105).  E2F-1 has 
been shown to be important in initiating etoposide-induced apoptosis and when over 
expressed can induce cell death (106).  In modulating E2F-1, Chk2 may have an 
important role in the DNA damage induced apoptosis pathway.  Chk2 can also interact 
with the checkpoint proteins BRCA1 and Promyelocytic Leukemia (PML) in the absence 
of DNA damage.  Following IR treatment both BRCA1 and PML are phosphorylated in a 
Chk2-dependent manner resulting in the loss of their abilities to bind Chk2 (73), an event 
which is important for cell survival after DNA damage.  Exactly how this modification 
impacts the function of these proteins remains unknown, although it has been 
hypothesized that these proteins may actively inhibit Chk2 activity in unperturbed cells 
(92).   
Chk2 does not become immobilized at sites of DNA damage but instead acts as a 
signal spreader, relaying the checkpoint signal to its downstream targets (107).  It initially 
interacts with 53BP1, γH2AX, and NBS1 in nuclear foci, but once activated it disengages 
from the complex (possibly by phosphorylation of PML or BRCA1) to seek out and 
activate its various substrates (108).  In patients with Nijmegen Breakage Syndrome who 
carry inactivating mutations in Nbs1, Chk2 fails to be activated showing that the MRN 
complex plays a central role in ATM/Chk2 activation after DNA damage (109).  Defects 
in the MRN complex have also been associated with radioresistant DNA synthesis (RDS) 
another link in the Chk2-DNA damage response pathway (110). 
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1.5.4 Chk2 and p53 
 Both Chk2 and p53 are tumor suppressors that play central roles in cell cycle 
arrest and in apoptosis, although conflicting results have made it difficult to ascertain 
exactly how these two proteins interact.  Chk2 was originally hypothesized to act 
upstream of p53 in mice, phosphorylating it at SER20 causing p53 stabilization and its 
dissociation from the p53-Mdm2 complex (62).  It was also shown that 
immunoprecipitated Chk2 is activated by IR to phosphorylate p53 and overexpression of 
Chk2 increased p53s transcriptional activity as demonstrated via a p53 responsive 
reporter plasmid (111).  However, other studies suggest that the interaction between Chk2 
and p53 may not be so straight-forward.  p53 does not have the Chk2 L-X-R-X-X-S/T 
substrate consensus motif at SER20, but other regions of the protein may instead act as 
substitute  Chk2 docking sites (112).  Several in vivo studies have failed to show the 
Chk2-p53 interation.  When Chk2 siRNA was introduced into human tumor cell lines p53 
stabilization was not affected (113) and when Chk2 was purified from tumor cell lines it 
was unable to phosphorylate either truncated or full-length versions of p53 (114).  These 
conflicting results suggest that the relationship between p53 and Chk2 may be stimuli and 
cell-type specific, and it remains to be determined exactly when Chk2 regulates p53 and 
what factors might compensate for the Chk2 role in cases where it is not required.  The 
downstream mediators of these p53-regulated cellular effects include GADD45 and the 
p21CIP1/WAF1 inhibitor of cyclin-dependent kinases and apoptosis promoting factors, Bax 





1.5.5 Conservation of Chk2 
 Chk2 appears to be highly conserved across a wide range of species, which is not 
surprising since all species need to be able to react to DNA damage or replication blocks.   
The first member of the Chk2 family to be discovered was the Saccharomyces cerevisiae 
homologue, Rad53 in 1994 (116).  It was subsequently discovered in fission yeast, 
Saccharyomyces pombe (named cds1) and in higher eukaryotes (117).  The human 
homologue was discovered in 1998 and was named Chk2 by the Elledge lab (57).  While 
Chk2 does show high levels of structural similarity it does have functional differences 
that are species specific. In yeast, Rad53 and cds1 can respond to a wide variety of DNA 
damage, while in mammals Chk2 activity seems to respond mostly to the most serious 
form of DNA damage, double strand breaks (118).  Work in D. melanogaster and 
C.elegans on Chk2 found new functions not documented in either mice or humans.  Mnk, 
which is the fruit fly homologue of Chk2, is highly expressed in the ovaries during 
embryogenesis suggesting a possible developmental role (119).  Loss of Chk2 in fly 
embryos has also been linked to an abnormal centrosome function wherein lethally 
damaged cells cannot be efficiently eliminated from the developing fly embryo (120).  
Loss of Chk2 also causes fly embryos to become resistant to radiation-induced apoptosis 
and prevents cell-death caused by an over-expression of p53 (121).  An interesting study 
done in C.elegans found that RNA interference of Cds1 (Chk2 homolog) resulted in 
failed meiotic recombination, a function not yet shown in other organisms (122).  In 
budding yeast, a distantly related kinase to Rad53 called Mek1 monitors meiotic 
recombination and it remains unknown which kinase is responsible for monitoring this 
process in mammals (123).  While the overall function of Chk2 does show some species 
specific variation, its general role seems to be conserved with the human Chk2 gene able 
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to complement checkpoint defects in both fission and budding yeast strains that are 
deficient in Cds1 and Rad53 respectively (57;124).     
1.5.6 Chk2 and Cancer 
 The first indication that Chk2 may act as a tumor suppressor came from a subset 
of patients with Li-Fraumeni syndrome, a disease that is typically associated with a 
germline p53 mutation.  These patients were atypical in that they still had two wildtype 
copies of p53 but a mutant form of Chk2, suggesting that mutations in the Chk2 gene 
may cause phenotypic consequences equal to TP53 inactivation (53).  A second 
indication that Chk2 may have a role in cancer development came when a Chk2 allele 
containing the mutation 1100delC, which results in a truncated C-terminus through the 
kinase domain, was found to cause an increased risk of breast cancer.  This result was 
independent of mutations in the BRCA1, breast cancer susceptibility gene (125). Further 
analyses have confirmed that truncated and mutated forms of Chk2 are unable to interact 
with and/or phosphorylate its primary downstream targets, p53 and Cdc25A (126).  
Mutations in Chk2 have since been associated with an increased cancer risk in prostate, 
lung, brain and lymphoid tissues (127).  Mutations in the kinase domain of Chk2 have 
been associated with faulty checkpoint activation after IR treatment and mutations within 
the FHA domain have been associated with accelerated Chk2 degradation and defects in 
its protein-protein interactions (90).  When Chk2 and p53 are both mutated, tumor cells 
have been shown to have a selective viability advantage over cells that have either 
mutation on its own.  This cooperative effect is probably due to the fact that p53 and 
Chk2 operate in the same DNA damage response pathway but also have independent 
functions (111).   
 A recent study by Bao et al. in 2006 showed that a subset of glioma tumor cells 
was able to become highly radioresistent and invasive due to a hyperactive DNA damage 
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response, which could only be attenuated by specifically inhibiting Chk2.  They 
concluded from this work that targeting the DNA damage checkpoint response in cancer 
cells could help overcome their radioresistance and provide a therapeutic model for 
malignant brain cancers (128).  
 In the future, Chk2 may become an attractive target in chemotherapeutic 
treatments.  Cancer cells often lack at least one cell cycle checkpoint and inhibition of the 
remaining checkpoints could make tumor cells more sensitive to anticancer therapies 
such as gamma-irradiation or DNA-damaging pharmaceuticals (84).  Normal cells could 
activate their other functional checkpoints and recover from the cell cycle arrest, while 
cancer cells effectively deprived of all checkpoints would undergo cell death. Some 
success has already been obtained in this pursuit such as ATM/ATR activity being 
blocked by caffeine (129) and inhibition of Chk1 by the anti-cancer drug UCN-01 (130), 
both of which resulted in decreased checkpoint activation and preferential cancer cell 
death after exposure to DNA damaging agents.    
1.6 Rainbow Trout (Oncorhynchus mykiss) as a Model Organism 
 There are numerous advantages to using rainbow trout as a model organism for 
carcinogenesis, including its known sensitivity to cancer-causing aflatoxins, nitrosamines 
and polycyclic aromatic hydrocarbons (PAHs) (131).  Rainbow trout are much less 
expensive to purchase and maintain than rodents and have an extremely low incidence of 
spontaneous tumors.  It has also been shown that many mechanisms involved in 
carcinogenesis are conserved between trout and mammals (132).  Rainbow trout are 
relatively portable, have wide-ranging body size, and are easily maintained in laboratory 
culture.  For these reasons rainbow trout has proven useful for statistically challenging 
studies, such as those studying low-dose response that require large numbers of animals 
to be statistically significant (132). 
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 The first study to link rainbow trout with carcinogenesis occurred in the early 
1960s when liver cancer was found in Pacific Northwest rainbow trout hatcheries.  This 
work eventually identified aflatoxin B1 as a human hepatocytic carcinogen (133).   After 
this discovery a major research effort was undertaken using rainbow trout as a model for 
cancer research at Oregon State University which primarily studies in vivo whole-animal 
responses to carcinogens (132).  Since then a variety of carcinogens have been tested on 
rainbow trout, although an understanding of the molecular basis for cancer initiation, and 
progression in rainbow trout has yet to be investigated.  It is currently unknown whether 
the DNA damage response pathway remains conserved relative to other eukaryotes, and 
there is little expectation that rainbow trout will surpass traditional rodent models in 
human cancer research.  The biggest limitation in using a teleost model is the lack of 
organ similarity to prostate and breast cancer.  Trout also have late sexual maturity (2-3 
years) and a long life span concurrent with somatic growth, which would make waiting 
for fish to finish development a considerable disadvantage (132).  In conclusion, a 
rainbow trout model offers distinct advantages and disadvantages relative to other 
organisms in the study of cell cycle control and carcinogenesis. 
1.7 Checkpoint Proteins in Fish 
 There have only been a handful of studies published that have examined the roles 
of checkpoint and DNA replication proteins in fish.  They have primarily centered on p53 
and a brief summary of the results to date are outlined below. 
1.7.1 p53 
 It has been previously shown that p53 is mutated in more than 50% of human 
cancers resulting in loss of p53 mediated apoptosis and cell cycle control (134).  p53 is 
highly conserved and has been cloned in a wide variety of fish species including Japanese 
medaka (Oryzias latipes) (135), coho salmon (Oncorhynchus kisutch), chum salmon 
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(Oncorhynchus keta), Chinook salmon (Oncorhynchus tshawytscha), puffer fish 
(Tetraodon miurus), barbel (Barbus barbus) (136), flounder (Platichthys flesus) (137), 
and zebra fish (Danio rerio) (138). In 2002, a study by Langheinrich et al. examined the 
roles of p53 and Mdm2 in zebrafish by generating separate p53 and Mdm2 deficient 
embryos.  Unperturbed p53 mutant embryos were indistinguishable from control 
embryos, while Mdm2 mutant embryos suffered high levels of cell death and arrested 
very early in development.  p53 deficiency did however result in decreased DNA-
damaged induced apoptosis after UV and camptothecin treatment suggesting a defective 
DNA-damage response (139).  This study concluded that zebrafish could act as a model 
organism for the development of anticancer drugs and treatments in cell cycle control. 
 A study by Berghmans et al. in 2005 further examined the phenotype associated 
with a p53 defective zebrafish mutant.  They verified the failure of embryos to undergo 
apoptosis after IR exposure and discovered that the mutants also failed to upregulate 
p21CIP1/WAF1 and to arrest at the G1/S checkpoint.  They also found that a third of the 
mutant embryos began to develop malignant peripheral nerve sheath tumors beginning at 
8.5 months of age (140).  In combination these two studies support the usefulness of 
teleost models in understanding the role of p53 in the DNA damage response.  
1.7.2 Separase, DTL/CDT2, mps1 and RB 
 Separase is a known tumor suppressor and mitotic regulator in vertebrates.  It was 
successfully cloned in zebrafish in 2007.  Separase was found to be the gene responsible 
for the improper segregation and genomic instability that was previously characterized in 
the cease&desist (cds) zebrafish mutant.  These mutants showed high levels of 
aneuploidy, polyploidy, spinal defects, and mitotic exit delays with an eight-fold increase 
in epithelial tumors (141). 
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 DTL/CDT2 is required for normal cell cycle control, specifically preventing 
rereplication, a role which is also conserved in humans.  A study using a zebrafish DTL 
mutant in 2006 showed that DTL acts by regulating CDT1, which is a protein required 
for pre-replication complex formation.  DTL associates with the CUL4-DDB1 E3 
ubiquitin ligase and is required for CDT1 downregulation through degradation after entry 
into S-phase.  This study also showed that DTL is required for the early G2/M checkpoint 
response (142).  
 Mps1 is a kinase that is required for the mitotic checkpoint.  Aneuploidy from 
chromosomal missegregation is a major cause of human birth defects and is caused by 
meiotic error.  A study by Poss et al. in 2004 found that Mps1 is a critical regulator of 
proper chromosome segregation in zebrafish and was able to demonstrate that even a 
slight disruption of the mitotic checkpoint can reduce the accuracy of chromosome 
segregation during nuclear division (143).   
 The RB gene has been cloned and characterized in a Xiphophorus interspecies 
hybrid of platyfish (Xiphophorus maculates) and swordtail (Xiphophorus helleri).  This 
study found that RB mRNA is expressed at a two-fold higher level in melanized skin and 
skin tumors versus muscle tissue, with corresponding higher levels of RB protein, 
suggesting that there is an change in expression level in RB in melanized cells (144).  
1.8 Molecular Biomarkers 
 There are currently a wide range of biomarkers being used worldwide to assess 
the impact of highly persistent pollutants on marine ecosystems.  Some of the more 
serious pollutants being monitored include polychlorinated biphenyls (PCBs), 
polychlorinated dibenzo-dioxins (PCDDs), polychlorinated dibenzo-furans (PCDFs), 
polynuclear aromatic hydrocarbons (PAHs), tributyltin (TBT) and other toxic metals 
which have been shown to accumulate in the tissues of various marine organisms (145).  
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Biomarkers at the cellular level act as an early warning system of the toxic effect of these 
pollutants before they can become concentrated through successive trophic levels of the 
food chain (146).  Biomarkers have been traditionally defined as the measurements of 
body fluids, cells, or tissues that indicate in biochemical or cellular terms the presence of 
contaminants or the magnitude of the host response (147).  Biomarkers can be 
molecular, cellular or whole animal, and change in response to both natural stressors and 
pollutants. In general, they should offer a specific and sensitive method for assaying the 
effect of pollution on a wide range of organisms (145).  Biological monitoring offers 
many advantages over environmental monitoring including being able to assess the 
internal dose of a compound, taking into account differences in absorption, excretion, and 
rates of DNA repair (148).  There are numerous criteria that have been suggested when 
evaluating a potential biomarker such as its potential usefulness in laboratory and field 
studies, the ability to determine routes of exposure, and the ability to provide temporal 
and spatial measures of pollutants (145).  The ideal biomarker should have a collection 
method that is simple and reliable, it should be specific for a particular type of exposure, 
it should reflect a subclinical and reversible change, and be ethically acceptable to use 
(148). 
 In marine systems several biomarkers have already been classified including 
cytochrome P4501A induction, acytelcholinesterase activity and metallothionein 
induction (145).  Cytochrome P4501A plays a key role in the breakdown of organic 
contaminants and is used as an indicator of exposure to organic contaminants such as 
PAHs, PCBs, and PCDDs.  Its enzymatic activity is measured using either fluorometric 
or spectrophotometric methods and the amount of enzyme can be characterized through 
ELISA (enzyme-linked immunosorbent assays) (149).  Acetylcholinesterase (AChE) 
hydrolyzes the neurotransmitter acetylcholine into choline and acetic acid.  AChE is 
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inhibited by organophosphorus and carbamate insecticides through irreversible binding of 
its catalytic site.  Its enzymatic activity can be measured using either spectrophotometric 
or delta pH metric measurements (150). Lastly, metallothionein (MT) is a non-enzymatic 
protein which specifically binds to heavy metals including zinc, copper, cadmium and 
mercury in both vertebrates and invertebrates.  MT levels are quantified using liquid 
chromatography and absorption spectroscopy (146). 
1.9 Research Aims 
 The overall purpose of this research project was to characterize Chk2 in 
Oncorhynchus mykiss and determine whether it could serve as a biomarker of DNA 
damage in fish.  Chk2 was chosen for this study because of its prominent role in the DNA 
damage response and because it has shown high levels of conservation in the metazoans 
studied to date. The specific goals are outlined below. 
1. Characterize the CHK2 gene in rainbow trout. 
2. Purify recombinant Chk2 protein. 
3. Generate anti-Chk2 polyclonal antibodies. 
4. Study the evolutionary conservation of Chk2 across metazoans. 
5. Characterize Chk2 at the transcript and protein level to determine tissue 
specific differences. 
6. Examine whether Chk2 can be induced in response to DNA damage in 
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Cell cycle checkpoints are critical for maintaining genomic stability, and function 
by monitoring DNA integrity and the successful completion of cell cycle events (151).  
Numerous checkpoint proteins work together to sense DNA damage and activate the 
DNA damage response, resulting in either DNA repair or programmed cell death 
depending on the severity and duration of the genetic injury. The expression level and/or 
phosphorylation state of these proteins changes in response to DNA damage, which 
provides a means of identifying cells that have activated a checkpoint response (152).   
   DNA damage is initially detected in eukaryotes by Rad9, Rad1, Hus1 (the 
heterotrimeric 9-1-1 complex), and Rad17 (12). These proteins form a PCNA-like sliding 
clamp, which binds DNA and activates the PIKK-like transducer kinases, ATM and ATR 
(25).  ATM resides in the cell as a homodimer, and responds primarily to DNA damage 
in the form of double strand breaks (DSB).  It is activated through phosphorylation by the 
9-1-1 complex, which causes its dissociation into monomers and initiates extensive 
autophosphorylation (153). ATR normally resides in the cell as a complex with its 
accessory protein, ATRIP.  This complex confers stability to ATR and is conserved in all 
eukaryotes, from budding yeast to humans.  ATR is activated by DNA adducts or stalled 
forks, which result in changes in its subcellular localization allowing the ATR/ATRIP 
complex to bind to RPA-coated single-stranded DNA (39). Both ATM and ATR are 
capable of phosphorylating serine or threonine residues in SQ/TQ sequences of the 
checkpoint kinases, Chk1 and Chk2.  Chk1 plays an important role in the DNA damage 
response and is phosphorylated in an ATR-dependent manner (154).  It was first 
identified as an essential protein in fission yeast and later in mammalian cells, but is not 
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essential for viability in budding yeast (155). Chk1 can be activated throughout the cell 
cycle and loss of Chk1 leads to mitotic failure and cell death (156). Chk2 is not an 
essential protein in mammalian cells, but its yeast homologue, Rad53, is essential for cell 
viability.  It is activated in an ATM-dependent manner in response to DSB and plays an 
important role in DNA-damage signaling. DNA double strand breaks can be generated by 
exposure to ionizing radiation or through contact with radiomimetic chemicals such as 
bleomycin. They can also arise as by-products of oxidative metabolism or through 
replication of damaged DNA.  If misrepaired, DSBs have the potential to lead to genomic 
instability and in higher eukaryotes, cancer predisposition or cell death (157). Once 
activated, Chk2 phosphorylates a variety of downstream targets including Cdc25A, 
Cdc25C, BRCA1 and p53.  Chk2 plays an important role in all the major checkpoints 
(G1/S, intra-S, G2/M) of the cell cycle by acting on the above-mentioned downstream 
targets causing cell cycle arrest, DNA repair or apoptosis (51).   
The link between CHK2 mutations and inherited cancer susceptibility was 
originally discovered by Bell et al. in 1999 (53) when three CHK2 germline mutations 
were found in families with classic Li-Fraumeni syndrome, a disease which is 
characterized by an increase in sporadic tumor risk in a variety of organ systems.  A 
subsequent study, looking specifically at the CHK2 1100delC mutation, which results in a 
truncated inactive form of the Chk2 protein, found that it increased the risk of breast 
cancer twofold and was associated with an earlier age of onset (158).  Infrequent somatic 
CHK2 mutations have also been found in lung cancer, ovarian tumor, vulval tumors and 
osteosarcomas (159-161).  The first evidence for the presence of CHK2 mutations in 
brain tumors was reported in 2005 by Sallinen et al. (162), who found the 1100delC 
mutation in a subset of human glioblastoma cases. A more recent study of murine 
primary brain tumors by Bao et al. in 2006 (128) showed that that the DNA damage 
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response, and Chk2 activity specifically, was upregulated in a subset of radioresistant 
tumors.  This increased activity enabled CD133+ glioblastomas exposed to ionizing 
radiation to efficiently repair DNA damage, increasing the survival and proliferation of 
these invasive tumor cells.   
Owing to its important role in cell cycle control and tumorigenesis, Chk2 has been 
studied in a wide range of species such as budding yeast, mice and humans.  However, 
few checkpoint proteins have ever been studied in fish, therefore the conservation of the 
DNA damage response across teleost species remains largely unknown. Rainbow trout 
(Oncorhynchus mykiss) was selected for this study because of its prominence as a 
sentinel for assessing water quality and ecosystem health, as well as its importance to the 
commercial aquaculture industry.  Rainbow trout is one of many species that is exposed 
to aquatic pollution and is well-suited as a model for checkpoint proteins in fish.  Of the 
checkpoint proteins that have been cloned and characterized the majority have been from 
zebrafish, including TP53 (138;140), MPS1 (143), DTL (142) and separase (141).  TP53 
has also been cloned in Japanese medaka (135) and European flounder (137) and the RB 
gene has recently been isolated in platyfish (144).  A DNA sequence analysis done by 
Krause et al. in 1997 (135) demonstrated a high degree of sequence similarity between 
the functional domains of Japanese medaka TP53 and other vertebrate taxa such as 
rainbow trout (Oncorhynchus mykiss), frog (Xenopus laevis), chicken (Gallus gallus), rat 
(Rattus norvegicus), mouse (Mus musculus), hamster (Mesocricetus auratus), green 
monkey (Ceropithecus aethiops) and human (Homo sapiens), suggesting that checkpoint 
genes are indeed highly conserved. The function of the TP53 protein was also shown to 
be conserved across teleosts, in a study by Berghmans et al. (140), where tp53-deficient 
zebrafish lines spontaneously developed malignant peripheral nerve sheath tumors due to 
a deficient cell-cycle arrest response to DNA damage.    
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 In the present report, we have isolated the CHK2 gene for the first time in fish, 
specifically Oncorhynchus mykiss, assessed its evolutionary conservation, characterized 
its tissue specific expression and examined its induction in response to DNA damage. 
This initial work will help to determine whether checkpoint proteins can serve as accurate 
biomarkers of genotoxic exposure in fragile aquatic ecosystems.  
 
2.2 Materials and Methods 
2.2.1 Whole Fish 
Rainbow trout (Oncorhynchus mykiss) weighing approximately 500 g were 
obtained from Rainbow Springs Hatchery, Thamesford, Ontario and held in well-water 
flow-through tanks at the University of Waterloo.  Fish were maintained at 13°C on a 
daily diet of  Classic Floating Trout Grower 5pt Regular pellets (Martin Mills, Elmira 
ON) and then euthanized by overdose with ethyl-3-aminobenzoate methanesulphonate 
salt (MS222; Sigma, St. Louis MO) followed by caudal vein exsanguinations.  Tissues 
were extracted and flash frozen in liquid nitrogen prior to storage at -80ûC.   
2.2.2 Fish Cell Lines 
 RTgill-W1 and RTbrain-W1 cell lines used in this study were derived from 
rainbow trout gill epithelium and brain respectively. RTgill-W1 is available from the 
American Type Culture Collection (ATCC # CRL 2523). The cell lines were routinely 
cultured in 25 cm2 culture flasks at 18 °C in Leibovitzs L-15 culture medium 
supplemented with 1% penicillin-streptomycin solution (100 µg/ml streptomycin, 100 
IU/ml penicillin, Sigma, St. Louis, MO) and 10% fetal bovine serum (FBS, Sigma, St. 
Louis, MO) for RTgill-W1, 15% FBS for RTbrain-W1. 
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2.2.3 Isolation of Fish Liver Genomic DNA 
Approximately 50 mg of adult rainbow trout liver tissue was weighed out and 
kept on ice in a sterile 1.5 mL microfuge tube.  550 µL of lysis buffer (50 mM Tris pH 
8.0, 20 mM EDTA pH 8.0, 1% SDS, 200mM NaCl, 1% 2-ME), 11 µL of 20 mg/mL 
proteinase K (Sigma, St. Louis, MO) and 5.5 µL of 10 mg/mL RNAse A (Sigma, St. 
Louis, MO) were added to the tube and it was incubated at 55ûC for one hour.  The tube 
was then centrifuged at 13 500 rpm for 10 minutes to pellet the debris, and the 
supernatant was transferred to a fresh microcentrifuge tube.  350 µL of 5M NaCl was 
then added and after vortexing, the tube was centrifuged at 13 500 rpm for 30 minutes at 
room temperature.  In a fresh tube, the supernatant was combined with 900 µL of ice-cold 
absolute ethanol and the DNA was allowed to precipitate out of solution.  The visible 
DNA was then removed from the ethanol and combined with 100 µL ddH2O in a fresh 
1.5 mL microcentrifuge tube and incubated at room temperature for 2 hours.  The 
concentration of the genomic DNA was determined by spectrophotometry and the 
integrity was assured by agarose gel electrophoresis.  
2.2.4 Isolation of Rainbow Trout CHK2 
A pair of degenerate primers was designed from two conserved amino acid 
regions (sp2 - 5ACGTAYAGCAARAARCAYTTYMG in the forkhead associated 
[FHA] domain and sp3 - 5AGCATYTGRTARAARTAGARYTT in the kinase domain) 
based on the alignment of human [AJ783839.1], mouse [BC056617.1] and zebrafish 
[AF265346.1] CHK2 orthologues obtained from Genbank (see Figure 2.1 for all genomic 
primer locations). PCR was performed using 17 µl LA Taq mix (TaKaRa, Shiga, Japan), 
1 µl each of the degenerate primers (10 µM) and 1 µl of rainbow trout genomic DNA (50 
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ng/µl) with the conditions of 95°C 5 min, 35 cycles (95°C 30 sec, 47°C 30 sec, 72°C 3 
min) and 72°C 5 min using a PTC-100 thermocycler (MJ Research, Watertown, MA).  
Following agarose gel electrophoresis, the expected 2 kb band was purified using an 
Ultrafree-DA spin column (Millipore, Billerica, MA), subcloned into pGEM-T Easy 
(Promega, Madison, WI) and fully sequenced using a Long-Read Tower automated 
sequencer (Visible Genetics, Toronto, Canada).  Based on this sequence, pairs of primers 
were designed for inverse PCR.  Aliquots of rainbow trout genomic DNA (5 µg) prepared 
by the method of Sambrook et al. 1989 (163), were digested in separate reactions with a 
restriction enzyme (BamHI, HincII, HindIII, Pdm I or Xba I) and purified by phenol 
chloroform extraction and ethanol precipitation.  A tenth of each digest (0.5 µg) was then 
subjected to self ligation using LigaFast System (Promega, Madison, WI) in a 10 µl 
reaction volume for 2 weeks at 4°C, and then heated at 70°C for 10 min after which the 
separate digests were pooled.  Inverse PCR was carried out with 17 µl LA Taq mix, 1 µl 
of each primer (10 µM): sp25 (5-TTGCTTTGATGACCCCATACT) /sp26 (5-
GTTGAGGACGACACTTGGTT), sp5 (5-TGGCGGATGAACAGTCCAAC) /sp26, 
sp29 (5-TCCAAATGGGACGGCATCTC)/sp28 (5-TGATATGCCACAACTGTCAG), 
sp29/sp30 (5-CTATCCATGCTGGCTTTTGC) and 1 µl of the template with the 
conditions of 95°C 5 min, 35 cycles (95°C 30 sec, Tm of primers - 5º 30 sec, 72°C 6 min) 
and 72°C 5 min using PTC-100 thermocycler (MJ Research, Watertown, MA).  Nested 
inverse PCR was done using the same conditions with 1 µl of the first PCR product as the 
template.  Two sets of inverse PCR to the 5 end, using primers sp27 (5-
ACTGAAGAAATCGCCCAGAT)/sp24 (5-CAACTGGTCATTCAGAACAG), sp1 (5-
TCGTTTGAATAGCCAAAAGA /sp24 and three sets to the 3 end, using primers sp31 
(5-TGAGGAGGCTTTACACCATC/sp28, sp31/sp30, sp18 (5-
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TTCAAATAACTTGGGCCAAG/sp31, covered the CHK2 gene.  Three clones from 
each nested inverse PCR were subcloned into pGEM-T Easy (Promega, Madison, WI) 
and sequenced. There was good sequence agreement between all three clones. 
2.2.5 cDNA Isolation of Rainbow Trout CHK2 
PCR was used to obtain a rainbow trout CHK2 cDNA fragment (see Figure 2.1 
for primer locations). One microgram of DNAse I treated total brain RNA from an adult 
rainbow trout was reverse transcribed with an antisense primer sp82 (5 
TAATGGAAACACTTAATGTT) corresponding to the region immediately downstream 
of the putative CHK2 polyadenylation signal (AATAAA), using the First Strand cDNA 
Synthesis Kit (MBI Fermentas, Burlington, Canada) in a 10 µl reaction.  The first PCR 
was performed with 17 µl LA Taq mix (TaKaRa), 1 µl each of sp82 primer (10 µM), 
sense primer sp51 (5ATGCCATGATAACCTGAATG) and the first strand cDNA under 
the conditions of 95°C for 5 min, 35 cycles for (95°C 30 sec, 45°C 30 sec, 72°C 3 min) 
and 72°C for 5 min.  The nested PCR was performed under the same conditions as the 
first PCR except that nested sense primer sp53 (5GACCATGTCCCAGGAGAAGC) 
was used, with the first PCR product as the template.  A PCR band of the expected size 
(1.9 kb) was gel-purified, subcloned into pGEM-T Easy (Promega, Madison, WI) and 
fully sequenced for both strands of six clones.  There was complete sequence agreement 
with no variability between all six clones. 
2.2.6 Isolation of CHK2 FHA fragment from a cDNA Library 
 Based on the sequence obtained above, the following sense primer, sp61 (5′- 
GGCTGCGGATCCAGCCATGGGGTCGCCTG) and antisense primer, sp62 (5′- 
GGCTGCAAGCTT GCACTTTATGGCGTTCCTCAGCTAGG) were employed to 
amplify the 300 bp forkhead-associated domain of the CHK2 gene from a rainbow trout 
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cDNA library (see Figure 2.1 for primer locations). These primers respectively 
incorporated BamHI and HindIII restriction enzyme sites (underlined).  The following 
PCR conditions were used for a 50µl reaction: 94°C 5 min, 35 cycles at (95°C 1 min, 
53°C 1 min, 72°C 1 min) and a final step of 72°C 5 min in an Eppendorf thermocycler 
(Mastercycler, Westbury, NY).  The PCR product was run on a 0.8% agarose gel, 
purified and subcloned in pGEM-T easy (Promega, Madison, WI) for sequencing. 
Sequencing showed complete agreement with expected results based on genomic and 
cDNA cloning of the CHK2 gene as described above. 
2.2.7 Multiple Sequence Alignment 
 The Chk2 sequences of the nine species used in the amino acid multiple sequence 
alignment and their Genbank accession numbers are listed in Table 2.1.  The 
Oncorhynchus mykiss amino acid sequence was obtained experimentally as described 
above. Sequences were corrected and assembled using BioEdit 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html).   The amino acid sequences were 
aligned using Clustal W on the basis of sequence similarity (164), and the alignment was 
finalized manually. Sequences were only included in the alignment if the sequence could 
be reliably aligned. An identity matrix that computes the quantitative degree of similarity 
between the individual amino acid sequences was also generated using BioEdit 
(Supplementary Figure 2.1).  A multiple sequence alignment of the same species 
comparing nucleotide sequence was also constructed (data not shown) and was used in 









2.2.8 Phylogenetic Analysis 
 To determine the appropriate evolutionary model for analysis of the data, the 
finished nucleotide alignment was run through ModelTest®, which established the 
process of DNA base-pair substitution that best fit the dataset (165).  The data was next 
analyzed using PAUP 4.0 (166) using maximum parsimony, likelihood, and neighbour-
joining methods.  For the analysis of the CHK2 dataset no outgroup was specified, as no 











          RN       MM      HS      CF      BT      PT      XL      TN      DR      OM 
R.norv  ID      0.925   0.854   0.843   0.843   0.793   0.631   0.514   0.583   0.597 
M.musc  0.925  ID      0.852   0.849   0.841   0.791   0.633   0.510   0.577   0.593 
H.sapi  0.854  0.852   ID   0.904   0.894   0.931   0.651   0.496   0.576   0.577 
C.famil 0.843  0.849   0.904   ID      0.922   0.839   0.658   0.508   0.573   0.578 
B.taur  0.843  0.841   0.894   0.922   ID    0.828   0.643   0.504   0.575   0.584 
P.trogl 0.793  0.791   0.931   0.839   0.828   ID      0.602   0.457   0.536   0.538 
X.laevi 0.631  0.633   0.651   0.658   0.643   0.602   ID     0.495   0.569   0.572 
T.nigro 0.514  0.510   0.496   0.508   0.504   0.457   0.495   ID      0.584   0.600 
D.rerio 0.583  0.577   0.576   0.573   0.575   0.536   0.569   0.584   ID      0.656 
O.mykis 0.597  0.593   0.577   0.578   0.584   0.538   0.572   0.600   0.656   ID 
 
Table 2.1: Species names and Genbank accession numbers of amino acid sequences 
used in the multiple sequence alignment. 
Supplementary Figure 2.1: Amino acid identity matrix generated by Bioedit.  
Shows sequence similarity between taxa from the Chk2 multiple sequence 
alignment.   
 48
suitable outgroup could be found in the literature.  In the maximum parsimony and 
neighbour-joining analyses the dataset was subjected to exhaustive searches and the trees 
were midpoint rooted.  In the maximum likelihood analysis the dataset was put through a 
heuristic analysis due to limited computational capacity and the tree was again midpoint 
rooted.  The maximum parsimony and neighbour-joining tree datasets were then 
subjected to bootstrap sampling (1,000 replicates) and the consensus tree was retained.   
The results of all three analyses generated trees with identical topology.   
2.2.9 Southern Blot Analysis 
Southern blot analysis was performed according to the protocol described by 
Fujiki et al. 2001 (167) except that Dra I, HincII, Pdm I and Pst I were used for digestion 
and CDPstar (Roche, Mississauga ON) was used for detection of the signals.  The DNA 
probe (201 bp) was prepared by PCR-amplifying the rainbow trout genomic DNA with 
the primers sp9 (5-TAGGGTCAAAAGCAAGAACC), /sp16 (5-
CCAAGATACTGGAGGAGTCT), followed by subcloning and labeling with DIG using 
PCR DIG Probe Synthesis Kit (Roche, Mississauga ON).  The authenticity of the probe 
was confirmed by sequencing as described above.   
2.2.10 RT-PCR  
Total RNA was extracted from rainbow trout peripheral blood leukocytes (PBL), 
head kidney, posterior kidney, spleen, liver, heart, gill, brain, intestine and muscle using 
Trizol (Invitrogen, Carlsbad, CA) according to the manufacturers protocol.  Total RNA 
was reverse-transcribed with Moloney mouse leukemia virus (MMLV) reverse 
transcriptase (RT) using a First Strand cDNA Synthesis Kit (Fermentas, Burlington, ON).  
The synthesized first strand cDNA was diluted 10-fold in dH2O.  The PCR reaction was 
conducted in a total volume of 20 µl, including 1 µl of the diluted first strand cDNA, 1 µl 
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of each PCR primer and 17 µl of LA Taq master mixture (TaKaRa).  PCR was performed 
in a PTC-100 thermocycler (MJ Research, Inc., Watertown, MA), using the following 
parameters: 95°C 5 min; 22-35 cycles at (95°C 30 s, 53-55°C 30 s, 72°C 1 min) and a 
final extension at 72°C for 5 min.  Oligonucleotides used as PCR primers are as follows: 
sp41 (5-CTTTGACAACAGTGGCAATG), and sp42 (5-
TTGACTCCTCTATCTGGTTC) to give a 481 bp product (primer locations are shown in 
Figure 2.1).  A primer pair for the ribosomal protein S11 transcript was prepared to be 
used as an internal control using 5′-AGCAGCCAACCATCTTCCAG and 5′-
ACTCTCCGACGGTAACAATG, as described in Nath et al (2006).  An aliquot (5 µl) of 
the PCR product was electrophoresed on a 1.3% agarose gel containing 1 µg/ml of 
ethidium bromide and photographed on a UV illuminator.  The intensities of the PCR 
amplicons in the gel were measured by NIH Image version 1.52, and relative intensity for 
each tissue was calculated by dividing the intensity of the CHK2 amplicon at 35 cycles 
by that of the S11 amplicon at 22 cycles. 
2.2.11 Expression Vector Construction 
 Following digestion with the appropriate restriction enzymes, the CHK2 FHA 
fragment was ligated into the BamHI and HindIII sites of expression vector pRSET A 
(Invitrogen, Carlsbad, CA) using T4 DNA ligase (Promega, Madison, WI) according to 
manufacturers protocol, transformed into the E. coli bacterial strain, DH5α (Life 
Technologies, Rockville, MD) and sequenced to verify that the insert was in frame with 
the N-terminal 6x His-tag. For expression of the recombinant protein, the construct was 





2.2.12 Protein Expression and Purification 
 A 5-ml overnight culture grown at 37°C with 200 rpm shaking and was used to 
inoculate 2 l of LB culture, containing 100 µg/ml of ampicillin. Cultures were induced by 
the addition of isopropyl-beta-D-thiogalactopyranoside to 1mM at an OD600 of 0.40.6. 
Cells were harvested 5 h after induction by centrifugation at 5,000×g for 10 min and 
lysed with 100 mM NaH2PO4, 10 mM TrisHCl, 8 M urea, pH 8. The supernatant was 
collected after centrifugation of cells in a Sorvall RC-5B ultracentrifuge (Du Pont, 
Newtown, CT) at 30,000 rpm for 30 min. Protein was purified using a Ni-resin column 
(Qiagen, Valencia, CA) as per the manufacturers instructions. In brief, 10 ml of crude 
cell lysate was incubated with 1 ml of Ni resin for 2 h at room temperature and then 
allowed to flow through an econo-column (BioRad Laboratories, Hercules, CA). The 
column was subjected to several rounds of washes each time using 1020 ml of urea 
buffer (100 mM NaH2PO4, 10 mM TrisCl, 8 M urea) at pH 8, 6.3, and 5.9. The Chk2 
recombinant protein was eluted in 1 ml aliquots using urea buffer at a final pH of 4.5, see 
Appendix I for immunoblot of purified recombinant protein. A Bradford assay (168) was 
performed concurrently with the elution steps to determine protein concentration. The Ni 
column washes and eluted fractions were separated on a 15% sodium dodecyl sulfate 
(SDS) gel and stained with Coomassie blue to assess purity. Purified recombinant protein 
was concentrated by combining 10 ml of the appropriate eluted fractions in dialysis 
tubing (Fisher Scientific, Ottawa, ON),  and incubating for 2.5h in excess polyethylene 
glycol (PEG 4000; Qiagen, Valencia, CA).  The sample was then dialyzed for 3 hours at 
4°C in 1L of 4M urea buffer, which effectively reduced the volume inside the dialysis 
tubing by half.  Subsequent sequential overnight dialysis steps at 4°C were performed 
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with 2M and 1M urea buffers.  A final overnight dialysis step at 4°C was performed in 
500 ml of 1xPBS.  The recombinant protein was then stored in 1xPBS; 0.02% NaN3 pH 
9.3, at 4°C at a concentration of 1mg/ml prior to use for antibody production.  
 
2.2.13 Immunization of Rabbits 
 Rabbits were immunized subcutaneously with an emulsion of 500 µl recombinant 
Chk2 protein (1 mg/ml) and 500 µl of Freunds incomplete adjuvant (Sigma, St. Louis, 
MO, USA). The rabbits were subsequently boosted three times with the same emulsion, 
at 3 week intervals. Blood samples were collected from the marginal ear vein of rabbits 
before every boost to assess antibody titers. Blood was allowed to clot at room 
temperature for 2 h and at 4°C overnight. Serum was separated by centrifugation at 
5,000×g for 8 min at 4°C (IEC 21000R). After the twelfth week, the rabbits were 
exsanguinated by carotid cannulation.  
2.2.14 Monitoring Antibody Titers 
 After each boost, serum antibody titers were evaluated by performing enzyme-
linked immunosorbent assay. Ninety-six well plates were coated with 100 µl of 10 µg/ml 
recombinant Chk2 protein diluted in coating buffer (15 mM Na2CO3, 34 mM NaHCO3, 
0.02% NaN3, pH9.3) and left overnight at room temperature. Each well was then blocked 
with 300 µl blocking buffer (1% BSA in TBS-T) at 37°C for 1 h, and then washed three 
times with T-TBS.  The primary rabbit antiserum (100 µl) was then added at different 
serial dilutions to the wells in four replicates and incubated for 1h at room temperature. 
Goat anti-rabbit IgG antibody conjugated to alkaline phosphatase (Sigma, St. Louis, MO) 
was used as the secondary antibody (1:5000) and after incubation for 1 h at room 
temperature, p-nitrophenyl phosphate tablets (Sigma, St. Louis, MO) dissolved in 20 ml 
distilled water was added as the substrate. The plates were incubated in the dark at room 
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temperature for 30 min then 50 µl of 0.03M NaOH was added to stop the reaction. 
Absorbance was measured at 405 nm using the SOFTmax PRO 2.6.1 program with a 
microplate reader (VERSAmax microplate reader, Molecular Devices). Readings were 
obtained after background correction. 
2.2.15 Whole Fish Protein Lysate Preparation 
 Brain and gill tissues were obtained from two adult rainbow trout as described 
above.  Tissues were measured out into 200 mg aliquots and each of these was combined 
with 500 µl NP-40 lysis buffer (10% Non idet P40, 1M Tris-HCL; pH 7.5, 5M NaCl) and 
50 µl protease inhibitor cocktail (Sigma, St. Louis, MO).  Samples were then sonicated 
using a Microson ultrasonic cell disruptor (Misonix, Farmingdale, NY) at medium 
intensity for 30 sec or until tissue was lysed, and centrifuged at 13000 rpm for 10 minutes 
at 4°C in a Biofuge-Pico centrifuge (Heraeus, Chandler, AZ).  Cleared lysate was 
transferred to 1.5 ml microcentrifuge tubes and stored at -20° C. 
2.2.16 Cell Culture Protein Lysate Preparation 
  RTgill-W1 and RTbrain-W1 cells were washed with 1 ml Versene (Gibco-
Invitrogen, Carlsbad, CA) solution and removed from the growing surface of the 25 cm2 
flat-bottomed flasks using 1 ml trypsin.  Cells were resuspended in 10 ml fresh 
Leibovitzs L-15 culture medium supplemented with 1% penicillin-streptomycin solution 
(100 µg/ml streptomycin, 100 IU/ml penicillin) (Sigma, St. Louis, MO), 10% fetal bovine 
serum (Sigma, St. Louis, MO) for RTgill-W1, 15% FBS for RT-BR, and then spun at 440 
x g for 5 minutes in an Eppendorf 5801R centrifuge (Hamburg, Germany).  Pelleted cells 
were washed in 1 x PBS and centrifuged at 13000 rpm for an additional 5 minutes in an 
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Eppendorf 5415 centrifuge (Hamburg, Germany).  The pelleted cells were then combined 
with 150 µl NP-40 lysis buffer (10% Non-idet P40, 1M Tris-HCL; pH 7.5, 5M NaCl) and 
protease inhibitor cocktail (Sigma, St. Louis, MO) and stored on ice for 30 minutes.  
Cells were then sonicated using a Microson ultrasonic cell disruptor (Misonix, 
Farmingdale, NY) at a medium intensity for 30 sec and centrifuged 13000 rpm for 10 
mins at 4°C in a Biofuge-Pico centrifuge (Heraeus, Chandler, AZ).  Cleared protein 
lysates were transferred to 1.5 ml microcentrifuge tubes and stored at -20° C. 
2.2.17 Determining Chk2 Antibody Specificity 
  RTgill-W1 protein lysates (45 µg) were boiled with 2x sample buffer (62.5 mM 
TrisHCl, pH 6.8, 20% glycerol, 2% SDS, 250 mM DTT, 10 µl saturated bromophenol 
blue) run in duplicate on a 15% SDS-PAGE gel according to standard protocols (163) 
and then transferred to 0.2 µm nitrocellulose membrane (Pall Life Science, Pensacola, 
FL). The first set of samples was detected with anti-Chk2 primary antibody (1:50), while 
the second set of samples was detected with final bleed anti-Chk2 primary antibody 
(1:50) that had been pre-incubated in excess recombinant Chk2 purified protein (1 
mg/ml).  The blots were then washed three times for ten minutes and probed using anti-
rabbit secondary fluorescent antibody (1:3000) (W647; Invitrogen, Missisauga, ON), and 
visualized using the Typhoon 8600 scanner (Amersham Pharmacia Biotech). 
2.2.18 Tissue Distribution  Cell Lines and Whole Fish 
 Protein lysates were harvested, as described above, for RTgill-W1 and RTbrain-
W1 cell lines.  45 µg of each sample was run on a 15% SDS-PAGE gel and transferred to 
a 0.2 µm nitrocellulose membrane, as described above.  The samples were detected using 
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final bleed anti-Chk2 primary antibody (1:50) and anti-rabbit IgG secondary fluorescent 
antibody (1:3000) (W647; Invitrogen, Missisauga, ON).  Chk2 was visualized using the 
Typhoon 8600 scanner (Amersham Pharmacia Biotech). 
Similarly, gill and brain protein lysates obtained from two adult rainbow trout 
were prepared as described above.  45 µg gill and brain samples from the two fish were 
run on a 7.5% SDS-PAGE gel and transferred to a 0.2 µm nitrocellulose membrane.  
Detection was performed as described above for the cell line protein samples. 
2.2.19 Bleocin Treatment to Induce Double Strand Breaks 
  RTgill-W1 and RTbrain-W1 cell lines were treated with either 3 mg/ml (low 
dose) or 18 mg/ml (high dose) (169) of Bleocin (commercial bleomycin), a radiomimetic 
agent that specifically causes a high proportion of double strand breaks (Calbiochem, San 
Diego, CA).  10 µl of each Bleocin stock solution was added to 10 ml Leibovitzs L-15 
culture medium supplemented with 1% penicillin-streptomycin solution (100 µg/ml 
streptomycin, 100 IU/ml penicillin; Sigma, St. Louis, MO), with 10% fetal bovine serum 
(FBS; Sigma, St. Louis, MO) for RTgill-W1 and 15% FBS for RTbrain-W1.   Cells were 
incubated at room temperature in the dark (Bleocin is photosensitive) for 1, 4, 8 or 24 
hours.  Protein lysates were harvested as described above.  35 µg of each protein sample 
was run as described above on a 10% SDS-PAGE gel and transferred to 0.2 µm 
nitrocellulose membrane.  The samples were detected using anti-Chk2 primary antibody 
(1:50) and anti-rabbit IgG secondary fluorescent antibody (1:3000) (W647; Invitrogen, 






2.3.1 The initial isolation of the rainbow trout CHK2 gene. 
 To design primers to obtain the full-length Oncorhynchus mykiss CHK2 sequence, 
a preliminary comparison between nucleotide human, mouse and zebrafish CHK2 
orthologues was conducted as described in materials and methods.  PCR was performed 
using a rainbow trout genomic DNA template, which produced an initial 2kb PCR 
product that was subcloned and sequenced.  Based on this initial sequence, pairs of 
primers were designed for inverse PCR reactions in an attempt to obtain the remaining 
CHK2 gene sequence. The genomic DNA template was digested in separate reactions 
with a restriction enzyme (BamHI, HincII, HindIII, Pdm I or Xba I), purified, allowed to 
self-ligate and then pooled as described in materials and methods.  Inverse PCR was 
done following the self-ligation reactions, and two sets of nested inverse PCR to the 
5end and three sets to the 3end allowed for the complete sequence to be obtained for the 
CHK2 gene. Three clones from each nested inverse PCR were subcloned into pGEM-T 
Easy (Promega, Madison, WI) for sequencing and in each case an identical CHK2 
sequence was obtained.  
cDNA cloning was also performed, using total brain RNA from a healthy adult 
rainbow trout. An initial PCR antisense primer (sp82) was designed to bind just 
downstream of the putative polyadenylation signal and was used with a sense primer 
(sp51) in the initial PCR reaction.  Using the first PCR product as a template a nested 
PCR using primer (sp53) was done to obtain the full CHK2 coding sequence (see Figure 
2.1 for primer locations). A PCR band of the expected size (1.9 kb) was obtained, gel-  
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AATTCTTATTTTCAATGACGGCCTAGGAACAGTGGGTTAACTGCCTGTTCAGGGGCAGAACGACAGATTTGTACCTTGTCAGCTCGGGGATTTGAACTTGCAACCTTCCGGTTAC   115 
TAGTCCAACGCTCTACCCACTAGGCTGCCCTGCCGCATGATGAATACATGGGCAGATCATTCAAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAACCAATCAATC   230 
               - 
AATCAATCAATCAATCTTTCATTCATATTCATAATGCACGGGGGGGGCTAGGATTCTCAGATGCAAGTTATACATGAGGACTTTGCTTAGTTTACGGACGTGGAAAATTGAAAGA   345 
sp51---------------        sp53---------------- 
TGCCATGATAACCTGAATGATGTTTTATTATTTACTTTAATAGACTGACTGAGGAGAAATATTGACCATGTCCCAGGAGAAGCCAGATGCTGGCAGCCAGACACAGTCGCAGCCT   460 
             --- 
CAGACTCAGTCCCAGAGTGGCTCCAGCTCCTCCTCTGGGTCAGGCACTGTCAGCTCAGTGGACACCATCCCTGTTAGGGACCTTGGCTCCATACCAGAAGAGCCTGAGCCACAGC   575 
sp61----------- 
CATGGGGTCGCCTGCTGCCTATGCAGAGAGGCTTCAGAGCCCACGgtgagtgcaaccacaagacatgccctgtttttttgggtagatagcccaaactgaaggtatcctgtgacag   690 
   sp1----------------- 
tcatggaatttttggatgacagatattgggtcagccaaatgatcggggtcaccgttttaatcgtttgaatagccaaaagaatagacgcacattttcgcctctgctctgctcctga   805 
ctgtatgtgctaccgcagcagtagggatgggggcgtagcccaaggaaaccgaagaccgtttgttacgacaccttgctgtttcagccatagagatccattctaattcctaattcta   920 
tggtttcagcaaggggcaactaggtttgatcacgttgtagagtccatgttacagcagaaacggactcaactgcacaaatgttcggctggcaatttttttggggggggctattatg  1035 
actgttcttttattttcataaaggtcttcatccataaccgtcggttatacagtgattgtgccagtcttaccttcaggattagctatggaattgtaacacgatatgtgctggctcc  1150 
atatctatctggcgttatggcttagcttctggaaaatgctgctacacatttttcaactaacctggtcttggaaatgctttcttcgttttgattcagaagaaaggtgtatcttata  1265 
aatgtttgtgtctagttacaggtggttttaccaacaacaacaaaaaaaacaggggaaaattctggaagctgtcaaaatccatgtttttgtactgtgcgaggagcttagccgctgc  1380 
acagctagcgtttcccagcatctttgcgctagtcggttctatgcggctaacgtgtagaagtagatgaccgtgcgtcacacagtgcagccaaaacaaagatctacacacatgccat  1495 
ttttcactcgatacaaaacatggattttaaaatctttctgaatttcctctggttttttgaagaaccacttgcaactggacacggacatttctaagatactttcttagttttcaat  1610 
ttagaagaaaagtgtatcaacaagactaggtataaaaataaaaataaaatgtagcagtgttttctattagctaagctgtcaacccagatatggagccgtcacatatcgtgttaca  1725 
attccgtcgctactgtaggcagtgaatacaggggcacgtttagttattgaacgttttgctacagtttgtactgaacaaaacgttttcccaccacggtgcgcaccattcctcaaca  1840 
ttttttgaggtatatttgatcccgtttgtgtgtggcggggtgggatctgctcaatatgggtgtgaccatttgaaatgtcaaactactgcagcagcacactgtacaaaatcgccct  1955 
       sp24---------------- 
ctgagccgccgtaatcagtcatcaaaatgttcttcaactggtcattcagaacagcacggtttccgttcaattgaacaacgttgtgtcctgctgaacgcggtccatgtgggaactg  2070 
 
tgcgcgcctgtgtgcagtttgctttgtttgtgtgagattctttgtatttctcaactagcagcattagcatctgtgtattctcttctctattgaagtgatggtgtttgactttttt  2185 
sp26----------------         sp25--------------sp27----------------      sp2--------------  
ttcagACTGTGTTGAGGACGACACTTGGTTTGGCCGGGACAGTAAATGTAACTATTGCTTTGATGACCCCATACTGAAGAAATCGCCCAGATTTGCTACGTACAGCAAAAAACAC  2300 
-----      
TTCCGAATATTCCGAgtaggtctattcatttgacaaaatgatgtatttcatgtttttgtttaacagtagtaaaatagttttgttcgcaatgtttgctcaagtgatgacggtcaga  2415 
       sp41----------------  
TcgttaccttgcagGAGCAGAACATTGTCTATGTCTTTGACAACAGTGGCAATGGCACGTTTGTTGACGGTACAATTCTTGGGAAAGGAAAAACTTTGCCTCTAGCAAACAATGC  2530 
 sp62------------------- 
GGTGCTGTCCCTAGCTGAGGAACGCCATAAAGgtaaccttgttacagagttttattttcaagtcatttctgttttaggtcactgatactcaaaagtcttagcattccactatatt  2645 
TgttccctgtcgctctcgacattaagtctacagcatcattcccttattggtgatgccggttttagttttttgcatttacaatccatgagattgatagtttcttccctcattagTG  2760 
          sp5----------------- 
TTTGTGTTCATTGATCTCATGGCGGATGAACAGTCCAACCTCCCCAAAGAGTTCAGTGAGAAATACCTGATTACCAGAAAGATTGGAGCgtaagtgagcattttgattcatttca  2875 
acttgtgaattttctgcaaaaatccagattttcgatttgaattacagagtgacattctagtatgatcaatgtgtgtaaacgtggctgataacgatttgtcgtaccagTGGTGTGT  2990 
GCGGGGAAGTGAAGCTGGCCTTTGAGAGGGCCACTTGCAAAAAGGTGGCTGTGAAGACCATCAACAAGAAGGACTTCCCAGCATCTGTCGGCgtaagtcttttcaccattttccc  3105 
cgtttcctagttgatgaatgttactgcaataaaaggaactcttctttgtgcaattctagACTGCCACACGAAATGCGGAACGAGAGATCCAGATCCTCCAAAGGATAAACCATgt  3220 
aagtaagtaatcattgtcatttttaatagcctgtttatacactgagttgtaccaaacattatgagcacctgctctttccatgactgatcaggtaaatccaggcgaatgccttgat  3335 
cccttattggtgtcacctgttgaatccacttcaatcagtgtcgatgaaggggaggagacgggttagggaaggatttttaattttaagccttgagacgtggattgtgtacgtgtgc  3450 
          sp30------------------  
tgtaaatgggcgagacaaaatatttaagtgctgttgaacggggtatggtagtaagtgtcaagaactgcaccgctgctgggtttttcaccgtcaacagtttcttgtgtgcatcgag  3565 
aatggtccaccacccaaaggacatccagccaaattgacacaactgtgggaagcattgaagtcaacatgggccaacatccctgtggaacgacatcttgtagagtccatgccctgac  3680 
aaattgatgctgttctgagggcaaaagggggggtgcaactcaatattaggaaggtcttcataatgattttacactcagtgtacatctataatgtattatgctgtaatgactgcca  3795 
aggaaaggagcctagtacattttcttgggggggggtagtcaaataccataaaagtagtcattttcaacttgtgttttctactggacaaagccacaatcataacatgttttttttt  3910 
ttttttttacatattcaacctgtatgtatgtatgtagtatttgcctgcaatttttctgtgtaactttttcctcctgtctattccagCCATGTCTGATCAAAACAGAAGACTTCTT  4025 
CCAAACAGACGACTCATACTACATTGTTTTAGAGCTgtgagtttagtatttaattcaagcagacacttttttaatatatttttatcaatggcaaaccagtatcattacattgcat  4140 
gtaatattttctgtagcccatctcagaagtacaattttcacaagcatcgtatttcctttccccttcgatttattctgtttcaactgaccgcatgtatgtgtttcagCATGGAGGG  4255 
      sp9-----------------        sp3------------------- 
CGGGGAACTCTTTGATAGGGTCAAAAGCAAGAACCAGATAGAGGAGTCAATTGCCGAGCTCTATTTCTACCAGATGTTGAAAGCAGTAGAGgtgggtggattgatgtatttctcc  4370 
  sp42--------------------- 
atttttttttcccatttcccaatttctagaagagtggtaggctttattaaataggctctgctgtgatgtcaaaatacgccataactatcttgttttatactggagatagttactg  4485 
tcacttgagtagttttacactgcttccttatgctggtttatttcacattccttccactagTATCTTCACAACAATGGCATCATCCACAGAGACCTCAAACCTGAAAATGTGCTGC  4600 
TTTCGTCTCAGGATGATGTTTGTGTCATCAAGgtaagatttgtcaattcatcatgtgggtaattttcccacaataattgaacatggtagatgaagtgtaagtgagggtagatagt  4715 
             - 
tatccacctggaaactcattgtcttcctgaagtgggggtggggggactgaaagcttggttgaagagtgacaggcctctctctctctatgtgacagATCACAGACTTTAATCAGTC  4830 
sp16--------------- 
CAAGATACTGGAGGAGTCTGCCCTGATGAGGACCCTTTGTGGAACACCCACATACCTTGCACCTGAGGTGTTCACCGACGCAGTCACCGTGGGCTACAGCAGAGCCGTAGACGCC  4945 
TGGAGTTTAGGGGTCGTCCTGTTTGTGTGgtagggatccatactactgatggcagggtaacataaatgacagtgctgcgtgctctgactagtaggaagtgccatgtaacttgttt  5060 
          sp18---------------- 
ctgtcaacatttaaagggaattgtaatgcaattatttcaattcattttcaaataacttgggccaagattacttttcaacagcacgcaaggttttcctgttcacagattcacataa  5175 
tttattaaactggagcttacttcctgtctccctcacagCTTGGCAGGCTATCCCCCGTTCCACCCTAATGCACAAACGGGTTTGTCAGTCAGGGATCAGATCACGCAGGGAATTT  5290 
     sp29-------------- sp28---------------- 
ATACATTTATTCCATCCAAATGGGACGGCATCTCGGATGATGgtaagagactactgtcaatcctgtttggctctgtcatgtgtgttagagcacatagaaattcgaaaacagatta  5405 
ttcctgtctcaggttgggaaagaactttgggtactttactacagtcgtattgataattccttaaatgctgtcccaatagttattttacttatccaatcatgtctagCGAAAGACG  5520 
          sp31---------------- 
TCGTGAAGAGGCTGCTTGTAGTGGACCCCAATGCCCGCCTCACCATTGAGGAGGCTTTACACCATCCCTGGCTGATGgtaagagctttattgccgtctctcattgcctggcccta  5635 
ctgccatcaaggcgggtacgtttactggatggaggggtatttggggctaggcagtgttgtaagtggcaacagtgaataatctctggtcccatcaatctccgtctcagGATGAGGC  5750 
CATGAAGGAGACTGCTGAATGCATCATGTACCCCAAGGACTCCGGAGATGCCACAGCGGCTGATGCCACAGCAGACTCCGTAGACACCACAGTAgtgagaaacgatgtcattcta  5865 
ctgcagcagtgtttcccacccctctcctgggggggaccactagacagttcatatttttgttgtagacctgcaccgacacagctgatttaacaaaggtcttggtgattagtgattc  5980 
cgtgtagggctagaacacacccacacacagagagagagaggggtgttgctaacaaaattgaactatggctcttgttactttagGCTTCAACTACAAAGAGGTCAAGAGAAGATGA  6095 
TGATGATGAGCAGCAGCCGGCAAAGAGGAGACCAGGCCCATCCACAGAGGCAACATGAGTCACATTTCATCCTCATCACCACATTGGAGACCCCTCCCCCCCAGGTAGTTTTCCA  6210 
CCGGCAATTTGGCCCCCTGGAAATCTACCAGTATATTGTATTTTATCACACTTCTATTGCTACATTTCCATTAACTTGTCAAATGATTTTAGAACGTTTGAATAGAAAAATAGAT  6325 
           sp82---------- 
GCGACAATTGCCTGCTGCGGTGCGTTTCCATTGAACTCTTCTGACGATAGAAACAGCTATATGTAATGGTCACACATACAAAAAAAAACAGTTTATAATAAAACATTAAGTGTTT  6440 
------ 
CCATTAAT                                                                                                             6448 
 
Figure 2.1: Rainbow Trout CHK2 Sequence and Location of Primers Used for Isolation and Characterization.  
Exons and introns are written in upper case and lower case, respectively.  Putative start and stop codons are in bold and 
in bold italics, respectively.  The number on the right side indicates the nucleotide position.  PCR primers used in the 
initial genomic cloning are highlighted in yellow above the genomic sequence they correspond to.  PCR Primers used in 
the cloning of CHK2 cDNA are highlighted in pink. PCR primers used for the cDNA probe in the CHK2 southern blot 
analysis are highlighted in green. PCR primers used in the CHK2 RT-PCR analysis are highlighted blue. PCR primers 
used to isolate the sequence encoding the FHA domain are highlighted in red.  The forkhead-associated domain is 





purified and sub-cloned into pGEM-T Easy (Promega, Madison, WI) and fully sequenced 
for both strands of six clones. Consensus was obtained between the six sequences.  Figure 
2.1 shows the O. mykiss CHK2 gene sequence with introns and exons indicated.  The 
obtained CHK2 DNA sequence in O.mykiss was 6448 bp encoding a protein of 508 
amino acids.  
2.3.2 The CHK2 gene sequence is well conserved and its phylogenetic evolution 
matches known speciation events. 
 
Having obtained a putative rainbow trout Chk2 sequence, a multiple sequence 
alignment was performed to assess the conservation of the Chk2 protein sequence among 
metazoans. The taxa names and Genbank accession numbers for the amino acid 
sequences used in the alignment are listed in materials and methods, Table 2.1.  
The amino acid sequences were initially aligned using ClustalW (164), then 
loaded into Bioedit® where the alignment was finalized manually and unalignable 
sequences were removed.  Other eukaryotes such as S. cerevisiae, C. elegans and D. 
melanogaster were not included due to lower sequence similarity with the metazoan 
sequences. Figure 2.2A shows the finalized amino acid multiple sequence alignment, 
with the experimentally derived rainbow trout Chk2 sequence showing a very high level 
of sequence similarity with the other metazoan species. Based on the finished alignment, 
an identity matrix was created, which provides a quantification of the degree of similarity 
between the aligned amino acid sequences (see Supplementary Figure 2.1).  This data 
suggests that the Chk2 protein is very highly conserved, consistent with a central role in 
the DNA damage response.  
Next, a phylogenetic analysis was performed to assess the evolutionary 





Figure 2.2A: Finalized multiple sequence alignment of Chk2 protein sequences.  A solid 
black background indicates conserved amino acids.  Full species names and Genbank 













Figure 2.2B:  Representative neighbour-joining phylogenetic tree of the CHK2 gene.  
Maximum parsimony and maximum likelihood trees were also generated and resulted in 
the same topology (data not shown). Common species names are: human (H. sapiens), 
domestic dog (C. familiaris), cow (B. taurus), house mouse (M. musculus), Norway rat 
(R. norvegicus), African clawed frog (X. laevis), zebrafish (D. rerio), pufferfish (T. 
nigroviridis)  and rainbow trout (O. mykiss).  Full species names and Genbank accession 
numbers are listed in Table 2.1 (materials and methods).  Bootstrap values were obtained 
after 1000 replicates for both neighbour-joining and maximum parsimony as indicated by 
























alignment. Based on the evolutionary model, GTR+I+G (general time reversible + 
proportion invariate + gamma), the dataset was analyzed by PAUP 4.0 using maximum  
parsimony, maximum likelihood, and neighbour-joining distance measures.  
Bootstrapping was done on both the maximum parsimony and neighbour-joining 
analyses.  All of the above analyses generated a phylogenetic tree with the same 
topology, and a representative neighbour-joining tree with bootstrap values (both 
neighbour joining and maximum parsimony) obtained after 1000 replicates is represented 
in Figure 2.2B. This tree conforms to known speciation events, and shows the taxa 
grouping in their expected clades with relative distance measures indictated.  All species 
used in this analysis form part of the Gnathostomata, or jawed vertebrate group (170).  
The ray-finned fish, or Actinopterygii group (171), which contains the pufferfish, 
zebrafish, and rainbow trout sequences, group together away from the mammalian 
species.  Within the mammals, the CHK2 sequences again cluster as expected, with the 
rodentia family grouping together apart from the larger mammals and primates (172).  
This analysis confirms that the evolution of the CHK2 gene matches known phylogenetic 
relationships. 
2.3.3 Characterization of the CHK2 gene: Copy number and mRNA tissue 
distribution. 
To further characterize the CHK2 gene in rainbow trout, a southern blot was 
performed to determine its copy number in the O. mykiss genome. The total genomic 
DNA was digested using various restriction enzymes (DraI, HincII, PdmI, and PstI), 
separated on a 1% agarose gel and transferred to a nylon membrane, as described in 






Figure 2.3: CHK2 gene copy number and mRNA tissue distribution. A) Southern blot 
of genomic DNA from O. mykiss probed with a 201 bp CHK2 fragment that overlaps the 
FHA domain (see Figure 2.1 for primers). Separate digests were done with DraI, HincII, 
PdmI, and PstI.  Results indicate that CHK2 is present as a single copy.  B)  RT-PCR gels 
showing the transcript expression levels of CHK2 in various rainbow trout tissues, 
independently verified from two fish.  Primers were designed based on highly conserved 
regions of the CHK2 gene.  Expression level results were normalized using an S11 gene 
transcript control.  PCR results were examined after 35 and 32 cycles for the CHK2 gene, 
and after 25 and 22 cycles for the S11 control.  CHK2 shows the highest level of 






Figure 2.1 for primer locations) of the CHK2 gene overlapping the FHA domain was 
allowed to hybridize to the membrane bound genomic DNA.  One prominent hybridizing 
band was detected for each of four single restriction digests, indicating a single copy of 
the CHK2 gene in the rainbow trout genome as shown in Figure 2.3A.  The faint banding 
pattern indicates that the probe may be binding to other genes containing an FHA 
domain. 
RT-PCR was then performed to determine CHK2 mRNA levels, using RNA 
extracted from head kidney, posterior kidney, spleen, liver, heart, gill, brain, intestine, 
and muscle, as described in materials and methods. CHK2 mRNA was found to be 
expressed most strongly in brain, posterior kidney, head kidney, spleen, and gill, although 
there was some variability in expression between the two fish analyzed. The CHK2 
mRNA levels were generally lower in muscle, peripheral blood leukocytes, heart, liver, 
and intestine (Figure 2.3B).  
 2.3.4 Production of recombinant Chk2 protein and specificity of polyclonal anti-
Chk2 antibodies. 
We next wanted to analyze the Chk2 protein in O. mykiss by creating a sensitive 
and reliable anti-Chk2 polyclonal antibody.  A new set of primers, sp61/sp62 (see Figure 
2.1 for primer locations), were designed to amplify a 300 bp region of the forkhead-
associated domain of the CHK2 gene. The forkhead-associated domain was chosen 
because it is a highly conserved region of the CHK2 gene that could potentially result in 
the generated antibodies being able to detect the Chk2 protein in other fish species 
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through cross-reactivity. PCR was performed as described in materials and methods, and 





Figure 2.4: Verification of Chk2 antibody specificity. A) Western blot showing 
detection of Chk2 polypeptide (49 kDa) using anti-Chk2 polyclonal antiserum (1:50). B) 
Western blot showing that these bands fail to be detected when the antiserum is pre-
incubated with recombinant Chk2 protein. 45 µg of two gill protein lysates from the 
rainbow trout RTgill-W1 (173) cell line were used to illustrate this specificity. Ponceau S 





confirming its identity through DNA sequencing, the CHK2 FHA fragment was cloned 
into the E. coli expression vector pRSET-A (Invitrogen, Carlsbad, CA), and used to 
generate recombinant protein, see Appendix I for immunoblot of purified recombinant 
protein.  Rabbit antisera generated against the recombinant Chk2 protein strongly 
recognized the recombinant and native forms of rainbow trout Chk2. To confirm the 
specificity of the polyclonal antibodies, a western blot was performed using either 
untreated final bleed anti-Chk2 antiserum or anti-Chk2 antiserum that had been pre-
incubated with excess recombinant Chk2 protein.  As shown in Figure 2.4, when the 
polyclonal anti-Chk2 antibodies were blocked with excess recombinant Chk2 protein 
they were no longer able to detect the Chk2 protein (49 kDa) in two samples of RTgill-
W1 rainbow trout lysates.  Due to the excess recombinant protein binding up all the 
available anti-Chk2 antibodies, the non-specific binding shown in Figure 2.4 A) was lost 
in Figure 2.4 B). Ponceau S staining served as an indicator of protein loading and 
integrity. These results indicate that the anti-Chk2 antibodies are highly specific to the 
Chk2 protein in rainbow trout. Chk2 often appears as a doublet throughout these 
analyses, which may indicate differentially phosphorylated forms of the Chk2 protein. 
2.3.5 Tissue specificity of Chk2 protein expression. 
 Since our initial RT-PCR analysis showed that CHK2 mRNA levels vary based on 
tissue type (Figure 2.3B), western blots were performed to determine if Chk2 protein 
expression levels were similarly variable. In contrast to what was observed for mRNA, 
the level of Chk2 protein was more abundant in gill tissue versus brain tissue (Figure 
2.5A). To confirm these observations, Chk2 levels were assessed using rainbow trout gill 
(RTgill-W1) and brain (RTbrain-W1) cell lines (173). Comparable to the results obtained 
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with the whole fish protein lysates, Chk2 protein levels were found to be much higher in 





Figure 2.5: Assessment of Chk2 protein levels in adult rainbow trout and rainbow 
trout cell lines.   
A) Whole fish: Western blot of gill and brain tissue from two adult rainbow trout.  
Protein lysates (45 µg) were probed with anti-Chk2 polyclonal antiserum (1:150 
dilution).  B) Cell lines: Western blot of RTgill-W1 and RTbrain-W1 (173) protein 
lysates (45 µg) probed with anti-Chk2 polyclonal antiserum (1:100 dilution). Detection 
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confirms presence of Chk2 protein (49 kDa).  Ponceau S staining is shown as a loading 
control. 
 
the initial barrier between fish and their external aquatic environment, and are the first 
tissues to come into contact with any toxins that might be present in the water.  The high 
levels of Chk2 protein may indicate that the DNA damage response is constitutively 
active or on alert in gill tissue, as cells respond to genotoxic agents present in the water. 
2.3.6 Effect of Bleocin induced DNA damage on Chk2 protein expression in RTgill-
W1 and RT-Brain. 
 Upregulation and/or phosphorylation of Chk2 in response to DNA damage has 
been shown in numerous species; specifically in response to double-strand breaks (DSB) 
(92).  RTgill-W1 cells were treated with either a low dose (3mg/ml) or a high dose 
(18mg/ml) of Bleocin, a commercial form of bleomycin, which is a radiomimetic drug 
that causes a high-percentage of DSBs in proliferating cells (169). Cells were harvested at 
1, 4, 8 or 24 hours post treatment and protein lysates were obtained for immunoblot 
analysis with anti-Chk2 antiserum.  As shown in Figure 2.6A and B, at both dosages, 
Bleocin has no effect on expression levels of Chk2 in RTgill-W1. Given our previous 
observations that Chk2 levels were constitutively high in untreated gill samples obtained 
from both cell lines and whole fish (Figure 2.5), it is possible that no upregulation or 
modification of Chk2 may be required in gill to respond to the double strand breaks 
caused by Bleocin under these treatment conditions. 
 Since levels of Chk2 protein are considerably lower in rainbow trout brain than in 
gill for both whole fish and tissue culture cells, we hypothesized that the levels of Chk2 
protein in rainbow trout brain might be upregulated or phosphorylated in response to 
DNA damage.  To investigate this possibility RTbrain-W1 cells were also treated with 
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Bleocin and protein extracts were analyzed by immunoblot. As seen in Figure 2.6C, 
untreated RTbrain-W1 cells show relatively low levels of Chk2.  When exposed to a low  
 
 
Figure 2.6: Effects of Bleocin treatment on the expression of Chk2. A) Western blot 
of RTgill-W1 protein lysates (45 µg) after exposure to a low dose (3 mg/ml) of Bleocin at 
indicated time points. B) Western blot of RTgill-W1 protein lysates (45 µg) after 
exposure to a high dose (18 mg/ml) of Bleocin at indicated time points. Untreated control 
samples are shown at 0h and at 24h. C) Western blot of RTbrain-W1 brain protein lysates 
(35 µg) after exposure to either a low dose (3 mg/ml) or high dose (18 mg/ml) of Bleocin 
at indicated time points. Untreated control samples for all time points are also shown. 
Samples were detected using anti-Chk2 polyclonal antiserum (1:100 dilution).  Detection 
 68
confirms presence of Chk2 (49 kDa).  Ponceau S staining of the membrane is shown as a 
loading control. 
 
dose of Bleocin (3mg/ml), Chk2 levels begin to increase after approximately 8 hours and 
remain high up to 24 hours after the initial exposure.  At the higher dose of Bleocin (18 
mg/ml), Chk2 levels begin to increase earlier, at approximately 4 hours, and again remain 
high up to 24 hours after the initial exposure.  There also appears to be a modest upward    
shift consistent with increased phosphorylation of the Chk2 protein. 
2.4 Discussion 
 The CHK2 gene has been successfully cloned for the first time in fish, specifically 
Oncorhynchus mykiss. The predicted peptide sequence of 508 amino acids is similar in 
length to the sequences from other teleost and mammalian species, which have an 
average length of approximately 520 amino acids. The sequence also shows high levels 
of conservation in the three distinct functional domains of Chk2: the SQ/TQ cluster 
domain (SCD), the forkhead-associated domain (FHA) and the Ser/Thr kinase domain 
(92). The deduced amino acid sequence for the rainbow trout Chk2 protein is 66% 
identical to the zebrafish Chk2 sequence and 57% identical to that of human Chk2 
(Figure 2.2A and Supplementary Figure 2.1) showing a high level of sequence similarity 
across metazoans. Likewise, a study by Cheng et al. in 1997 found that the tumor-
suppressor TP53 amino acid sequence in zebrafish was 63% identical to the predicted 
TP53 sequence in trout and 48% identical to that of human TP53 (138).  Therefore, the 
rainbow trout Chk2 sequence makes an important contribution to the growing body of 
knowledge showing the high level of conservation in checkpoint proteins and their roles 
in the DNA damage response. 
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 To further characterize their evolutionary relationship, complete Chk2 amino acid 
sequences from rainbow trout and other metazoans were used to create a neighbour-
joining phylogenetic tree (Figure 2.2B). As expected, teleost sequences clustered together 
with high confidence, while mammalian sequences formed their own distinct clusters. 
Interestingly, most of the bootstrap values are very high, which indicates that the 
branching order has a strong level of confidence. The one exception is the branch that 
encompasses the trout and pufferfish sequences, indicating that the analysis can not 
distinguish with a high level of certainty which of these two species has the highest 
sequence similarity to the zebrafish sequence, as more teleost sequences become 
available this grouping should become more definitively resolved.    
 In characterizing the gill and brain tissue distribution of the Chk2 protein there 
was strong agreement between fish tissue samples and the immortalized rainbow trout 
cell lines maintained in the laboratory (Figure 2.5).  This indicates that rainbow trout cell 
lines can accurately reflect the tissue-specific expression of checkpoint proteins occurring 
in vivo, making it possible to characterize checkpoint responses at the cellular level 
without exposing live animals to genotoxic agents.  In a recent study by Kales et al. in 
2007, a rainbow trout macrophage cell line was used to assess the effect of parasitic fungi 
on the immune system of rainbow trout, which showcased another example of using cell 
lines to look at molecular processes of fish in response to stress conditions. They were 
able to conclude that, similar to in vivo processes, rainbow trout monocyte/macrophage 
cell line, RTS11 was activated in response to both live and heat-killed water mold 
mycelium and their culture filtrates (174). The power of using cell lines in the laboratory 
provides a huge economic advantage over treating whole fish and facilitates the control 
over external variables in the continuing characterization of checkpoint proteins in fish. 
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 In analyzing the expression levels of the CHK2 transcript and the Chk2 protein 
there were interesting differences within rainbow trout gill and brain tissues.  At the 
transcript level, gill tissue was shown to have a much lower level of CHK2 versus 
rainbow trout brain tissue, while at the protein level the reverse was true.  Figure 2.3B 
shows that gill tissue has a relatively low level of CHK2 transcript, although this result 
shows some variability (relative values of 0.32, 1.01 to the S11 control); while in brain 
tissue, the CHK2 transcript is higher than in any other tissue (relative values of 1.97, 2.78 
to the S11 control). At the protein level, Chk2 seems to be much more strongly expressed 
in gill in comparison to the low levels of protein seen in brain tissue.  As discussed above 
this result was seen in both cell culture and fish tissue samples (Figure 2.5). Constitutive 
expression of Chk2 protein in rainbow trout gills, may relate to the innate property of 
gills acting as the main barrier between the fishs internal and external environments. 
Previous studies have shown that the gills often show upregulated immune system 
proteins such as clottable protein (175), toll-like receptors (176), and IL-6 (177).  The 
constitutive expression of checkpoint proteins, such as Chk2, may act in a similar 
fashion, protecting the fishs internal environment from external stresses or pollutants. 
Rainbow trout gill cells in culture also have a very fast growth rate and can reach 
confluency in 3-5 days (178).  In vivo, this quick growth rate helps to replace cells that 
have been sloughed off under the constant bombardment of swiftly moving water. 
Consequently, Chk2 is likely maintained at high levels in gill for two reasons: to 
safeguard the fidelity of DNA replication in these continuously proliferating cells and to 
ensure that DNA damage caused by any pollutants that come into contact with the gills 
can be dealt with efficiently. In contrast, rainbow trout brain cells proliferate at a much 
slower rate than gill cells, taking approximately two weeks to reach confluency (179).  
The brain is relatively well protected from the external environment with genotoxic 
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agents only reaching it after entering the blood stream and crossing the blood-brain 
barrier. Under normal conditions, Chk2 may therefore be maintained in the brain in the 
form of a transcript reservoir, with high levels of CHK2 mRNA (Figure 2.3B) and low 
levels of Chk2 protein (Figure 2.5).   
The activation of Chk2 in response to DSB has been well-characterized in a 
variety of species including humans, mice and yeast (where it is called Rad53) (92).  
Typically, Chk2 is activated through phosphorylation by ATM following DNA damage 
and propagates the signal through phosphorylation of downstream targets involved in cell 
cycle progression or apoptosis (55). A recent study by Roy et al. in 2006 showed that 
Chk2 activation is not only controlled by phosphorylation but can its levels can also be 
upregulated in response to DNA damage as shown by Nimbolide treatment, a natural 
triterpenoid that causes cell cycle arrest in human colon carcinoma HT-29 cells (180).  
Bleocin, the radiomimetic drug used in the present study, has been shown to cause a 
significant number of double strand breaks and induce cell cycle arrest in proliferating 
human cells, while still allowing a large number (>70%) of cells to survive at least 24 
hours after the initial treatment (169). As shown in Figure 2.6C, Chk2 levels clearly 
increase in rainbow trout brain cells in response to Bleocin treatment. This result in 
combination with the high-levels of brain CHK2 transcript (Figure 2.3B), supports the 
notion that Chk2 is maintained in a transcript reservoir and is translated in response to 
DNA damage. It is also apparent from the quick response, within 1 hour, that the 
translation must be from existing transcript as new CHK2 transcript could not be 
synthesized within that time-frame.  This increase in Chk2 protein was shown to be dose-
dependent with levels increasing much more quickly after a larger dose (18 mg/ml) than 
after a smaller dose (3 mg/ml), presumably since a higher dose would result in 
significantly more DNA damage, and require significantly more Chk2 activity to initiate 
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a successful DNA damage response.  Previous work has found high levels of Chk2 
protein in a subset of human and murine brain tumors exposed to ionizing radiation 
(128;162), the conservation of this relationship highlights the importance of the Chk2 
protein in responding to DSBs in brain tissue. The rainbow trout gill tissue did not show 
this same response (Figure 2.6B), as Chk2 levels remained constitutively high regardless 
of dose or exposure time to Bleocin treatment.  This supports the notion that due to their 
constant contact with the external environment and high rate of proliferation gills 
maintain a consistently higher level of protective checkpoint proteins.  
In summary, Chk2 protein levels in rainbow trout brain cell lines can serve as a 
sensitive indicator of double strand breaks in response to genotoxic damage, while gill 
cell lines appear to have a constitutively high level of Chk2 expression.  Our work also 
demonstrates that cell lines in the lab can accurately reflect the protein levels documented 
in samples obtained from fish tissue.  Finally, this study is the first to clone and 
characterize Chk2 in a fish species. The characterization of additional checkpoint proteins 
in rainbow trout could lead to the development of a biological assay to test the quality of 
water samples for the presence of genotoxic agents.  The nature of the checkpoint 
response and the subset of checkpoint proteins activated can vary considerably depending 
on the nature of the DNA damage and the stage of the cell cycle during which it occurs 
(35).  Using specific cell cycle checkpoint proteins as biomarkers, a sensitive and specific 
system could thus be created to measure the environmental impact of water genotoxins 
on aquatic ecosystems and assess the potential risks for human health.   
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3.1 Research Contributions 
Very few checkpoint proteins have ever been studied in teleost species and this 
study was the first to characterize Chk2 in fish.  It is also the first time a checkpoint 
protein has ever been characterized in Oncorhynchus mykiss, demonstrating the potential 
for a rainbow trout model in creating a checkpoint protein centered biological assay. 
While several genes have been characterized in other fish species as described in Chapter 
1 Section 7, this research was the first to apply several novel methods in examining 
checkpoint proteins in fish.  This study was the first to look at the state of a checkpoint 
protein in whole fish tissue samples versus fish cell lines and show that cell lines 
accurately reflect the state of a checkpoint protein found in vivo.  This knowledge will be 
useful in allowing future researchers to use cell lines instead of live animals, which are 
much more difficult to maintain in a laboratory setting and far less cost-effective. This 
study was also the first to presumably induce double strand breaks in a fish cell line and 
to effectively demonstrate an upregulation of a checkpoint protein in response to such 
treatment.  Other work has compared the levels of Rb and p53 in tumor cells lines versus 
wildtype cell lines (139;144), but none have demonstrated an upregulation or post-
translational modification in response to experimentally induced double strand breaks.  
This result provides the first step in showing that checkpoint proteins can be used to 
assess the exposure of fish to genotoxic agents present in their environment. Lastly, this 
study was pioneering in that it compared the tissue specific differences of the DNA 
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damage response in fish.  This article was the first to show that checkpoint proteins 
appear to be consituitively active in gill, acting as a first line of defense against genotoxic 
agents present in the fishes external environment.  This finding fits with the unique 
physiology of fish, where nothing in the water can enter the fishs bloodstream without 
first being filtered through the gill barrier. This study was also the first to show that in 
unperturbed brain cells, Chk2 protein levels are low but in response to genetic insult 
brain cells are capable of upregulating the levels of Chk2 present to mount a serious 
defense against DNA damage.  This result was further confirmed by the initial RT-PCR 
finding that the Chk2 transcript is elevated in this highly sensitive tissue, and is thus 
prepared to initiate a DNA damage response in the event that a genotoxic agent crosses 
the blood brain barrier.  By demonstrating that the changes in checkpoint proteins vary 
based on tissue type, this study was able to show that the physiology of fish has an 
enormous impact on how different tissues respond to genotoxic stressors. 
 
3.2 General Discussion 
 
The ability to detect genotoxicity in aquatic organisms caused by natural or 
anthropogenic stressors is an area of interest to many government and industrial parties.  
As human populations continue to grow and levels of pollution continue to rise the ability 
to understand the subtle effects of long term exposure to fish becomes increasingly 
important.  Whether through chemicals in municipal wastewaters or through industrial or 
agricultural run-off very little is known about how these toxins are affecting the fish that 
habituate Canadian waterways.  The ability to characterize the effects of such exposure 
on fish growth, reproduction and disease resistance will be greatly beneficial in 
understanding what preventative measures should be taken to protect this important 
natural resource.  This study is the first step in creating a bioassay that would use in vitro 
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genotoxicity testing in cell lines to determine the effect of industrial effluents and 
contaminants on feral fish species.   
 The Government of Canada has designed a Water Quality Index (WQI) scale that 
currently assesses water quality based on the following parameters: dissolved oxygen, 
pH, total phophorus, total nitrogen, arsenic, lead, mercury and pesticides (181).  While 
the guideline values for these indicators were originally derived using test organisms, the 
actual impact of these variables on aquatic species remains largely undetermined.  
Currently, there is no quick and easy way to assess biological impact on aquatic life and 
there is an undeniable lack of uniformity in techniques that are currently being employed 
(145).  This presents a need for a reliable and cost-efficient method to assess the impact 
of a wide range of pollutants at a biologically relevant level. 
 As described in Chapter 1 and reviewed in Sarkar et al. 2006, there are currently a 
number of methods being used as biological indicators of pollution.  Primarily, 
Cytochrome P450 activity, acetylcholinesterase activity, metallothionein levels and DNA 
integrity have all been described as methods for understanding the biological impact of 
aquatic pollution (145).  Unfortunately these methods have serious drawbacks which 
limit their use and relevance as biomarkers.  For example, DNA integrity is currently 
assessed using either a comet assay (182) or an alkaline unwinding assay (183) both of 
which have serious limitations.  The comet assay monitors the degree of fragmentation in 
DNA by anchoring cells in an agarose gel, lysing them and assessing the amount of 
migration away from a central core of intact genomic DNA during electrophoresis (184).  
However, this assay would not be sensitive enough to assess the small amounts of 
damage that would be present in aquatic specimens since integrity of DNA can only be 
detected when >20% of the DNA appears in the tail (i.e. the portion that migrates away 
from the genomic core) (185).  The alkaline unwinding assay measures the extent to 
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which strand breaks aid in denaturation (186), however many genotoxic agents can 
inhibit enzymes that are required for this process to occur naturally, such as 
topoisomerases and DNA polymerases (187).   
 In awareness of these issues, an alternative method of assessing genetic damage 
could be to use cell cycle checkpoint proteins as biomarkers.  As described in Chapter 1, 
checkpoint proteins are activated when DNA damage arises and act to slow down the cell 
cycle, direct repair processes or initiate apoptosis (35).  The DNA damage response 
typically causes either an upregulation or a post-translational modification of these 
checkpoint proteins providing a quantifiable and observable change in cells exposed to 
genotoxic agents.  Interestingly, the subset of checkpoint proteins activated and the 
degree of activation varies considerably depending on the type of DNA damage and the 
point within the cell cycle when it occurs (35).  These features of checkpoint proteins 
present a promising approach for assessing the quality of polluted water using a panel of 
relevant checkpoint biomarkers to determine the degree and type of genetic stressor 
present in each sample.  Some examples of DNA damage that could be characterized 
using checkpoint proteins include single strand nicks, double strand breaks, DNA adducts 
and intercalation.       
 This study presents the first step in developing a cell cycle checkpoint protein 
biological assay.  The checkpoint protein, Chk2 was shown to be upregulated in rainbow 
trout brain cells in response to double strand breaks caused by a radiomimetic agent.  
This result parallels findings with mammalian cells that Chk2 is a central player in the 
DNA damage response to double strand breaks.  While these results are encouraging 
more work remains to be done in the creation of a biological assay using cell cycle 
checkpoint proteins as described below. 
3.2 Future Work 
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 In the development of the cell cycle checkpoint bioassay the first objectives will 
be to clone additional fish checkpoint genes, express the corresponding recombinant 
protein and develop highly specific polyclonal antibodies.  As described in Chapter 2, 
genes will be initially isolated using PCR primers based on areas of high sequence 
similarity to genomic databases currently available, such as pufferfish and/or zebrafish.  
Rainbow trout templates will continue to be used in the cloning of the additional 
checkpoint genes as numerous high quality cDNA libraries are currently available at the 
University of Waterloo.  The first set of checkpoint genes that should be cloned includes 
TP53, MPS1, DTL and Separase as they have already been identified and characterized in 
other fish and are central components of the DNA damage response (see section 1.7).  
Two separate regions of each gene will then be used to produce recombinant proteins, 
one of which will be used to immunize rabbits, while the other will be used to immunize 
chickens.  All antibodies will then be assessed to determine their initial sensitivity and 
specificity in unperturbed rainbow trout cell lysates before being used in any future 
assays. Once a set of reliable antibodies has been created, the evaluation of their 
usefulness in detecting changes in checkpoint protein expression or modification would 
need to be determined in cell lines exposed to an arsenal of genotoxic agents, chemicals, 
and pollutants.   
Several genotoxic agents will be examined in an initial assessment to determine 
how different checkpoint proteins respond to various forms of treatment.  DNA 
methylating agents such as methylmethane sulfonate (MMS) and N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG) have been used for decades as classical DNA damaging 
agents. MMS and MNNG modify DNA by adding methyl groups to a number of 
nucleophilic sites on the DNA bases, although MNNG produces a greater percentage of 
O-methyl adducts.  Recent work in mice has shown that DNA methylation can be 
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detected by both ATM and ATR, which in turn activate downstream target genes such as 
BRCA1 and p53 (188).  Also, DNA damaging agents involved in replication fork stalling 
and ATR-mediated checkpoint activation such as Aphidicolin, a DNA polymerase 
inhibitor, and hydroxyurea, an inhibitor of ribonucleotide reductase which depletes dNTP 
pools, will be studied (189).  Finally, agents involved in double strand breaks such as 
bleomycin and ionizing radiation will continue to be examined.  The induction of double 
strand breaks is known to be preferentially detected by ATM and results in a Chk2-
mediated DNA damage response. 
 The rainbow trout model used in this assay was chosen because of its importance 
to the aquaculture industry and the availability of a number of rainbow trout cell lines at 
the University of Waterloo.  In the initial stages of this continuing project several 
rainbow trout cell lines will be screened to determine which provide the most consistent 
and robust response in checkpoint protein changes, beginning with RTL-W1 from liver 
(190), RTgill-W1 from gill (173) and RTbrain-W1 from brain (under characterization).  
RTL-W1 has been useful in evaluating exposure to dioxin-like compounds (191) and 
RTgill-W1 and RTbrain-W1 have been useful in characterizing Chk2 as described in 
Chapter 2.  The cell lines will be assayed for their sensitivity and reliability, the strength 
of their checkpoint response, their ease of maintenance and their tolerance to exposure 
manipulations.   
 There are many advantages to using cell lines instead of whole fish or tissue 
samples. Results are more reproducible and cell lines are far easier and more cost-
effective to maintain versus live animals.  As shown in Chapter 2 - Figure 5, RTbrain-W1 
and RTgill-W1 accurately reflect the native state of checkpoint proteins in live tissue, 
thus demonstrating the applicability of results obtained through rainbow trout cell 
cultures.  Cell lines provide a rapid means for harvesting protein lysates, which can than 
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be used to determine increases in levels of checkpoint proteins and/or reduced mobility of 
the checkpoint proteins, as hyperphosphorylation is often indicative of checkpoint protein 
activation (192).   As shown in Chapter 2  Figure 6, increased levels of Chk2 became 
apparent in a dose-dependent manner after exposure to the genotoxic agent, bleomycin.  
As additional checkpoint protein polyclonal antibodies become created rainbow trout 
checkpoint activation for a variety of specific DNA damage types will be assessed.  
Water samples will be taken from a variety of sites and following exposure to the 
samples, protein extracts will be subjected to immunoblot analysis and a characteristic 
biotoxicity scale will be developed.   
 Following the immunoblot analysis described above, antibodies that are able to 
detect changes in protein level will be used to develop a sandwich ELISA assay (193).   
Essentially, a sandwich ELISA involves binding a capture antibody to the wells of the 
microplate, adding a sample containing the target protein, and then adding a detection 
antibody generated in a second species that also binds the target protein and can be 
detected using an alkaline phosphatase-conjugated seconday antibody.  The addition of p-
nitrophenylphosphate results in an observable colour change which can then be 
quantified by optical density in a microplate reader.  The use of a sandwich ELISA will 
permit the mass production of microplates with antibody coated wells, allowing for a 
more rapid screening method than if the wells had to be bound by protein extracts from 
the cell lines for each assay run.   
 Antibodies that detect checkpoint protein activation based on changes in protein 
mobility will not be used in the sandwich ELISA, but will instead undergo immunoblot 
analysis.  In order to increase the efficiency of this assay protein extracts exposed to 
different water samples will be run in parallel lanes on the same gel (alternating with size 
marker), and transferred to a nitrocellulose membrane which will than be cut to separate 
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the lanes and placed in separate compartments on an incubation tray.  Different 
checkpoint protein specific antibodies will then by added to each compartment and 
detected using the appropriate fluorescent secondary antibody.  Duplicate sets of 
detections will be carried out using the antibodies obtained from chicken and rabbit to 
verify the accuracy of the results.   
3.3 Closing Remarks 
The use of checkpoint proteins as a means of monitoring genotoxic agents in the 
environment could serve as a way of early detection for harmful pollutants.  In 
combination with cell lines an assay could be performed quickly and easily using only a 
small sample of polluted water and not harming any live animals.  As the human 
population continues to grow and pollution levels continue to increase, a sensitive and 
specific scale could have enormous economic advantage in protecting the commercial 
fishing industry and maintaining clean and safe waterways.  In conclusion, this research 
project offers preliminary evidence to support the notion that the induction of the DNA 
damage response and cell cycle checkpoint proteins could potentially serve as a valid and 
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Protein purification of recombinant Chk2. Protein expression conditions were 
optimized and purification was done using an Ni-NTA agarose resin and column 
purification system.  Washes were done with decreasing pH to elute the protein of 
interest. A) Ponceau S staining showing all washes. Lane 1: pre-stained high molecular 
weight marker. Lane 2: pH=8 unwashed lysate.  Lane 3: pH=8 washed lysate.  Lane 4: 
pH= 6.3. Lane 5: pH=5.9. Lane 6: pH=4.5(1st wash). Lane 7: pH=4.5(2nd wash). Lane 8: 
pH=4.5(3rd wash). Lane 9: pH=4.5(4th wash). Lane 10: pH=4.5(5th wash).  Chk2 protein 
was eluted in the 3rd wash at pH=4.5.  B) Western blot using Anti-Xpress primary 
antibody, specific for an epitope attached to the protein of interest by the pRSET-A 
expression vector.  The Chk2-recombinant protein is visible in Lane 8 (eluted in the third 
wash at pH=4.5).  
 
 
